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ABSTRACT 
Neuroblastoma (NBL), the most common non-Central Nervous System (CNS) 
solid tumor of childhood, characteristically displays heterogeneous clinical presentation 
and biological behavior. Previous work has studied the genetic basis of the disease and 
revealed a low somatic mutation burden. In order to identify novel therapeutic targets and 
better understand the biology of high-risk NBLs, I investigated whole transcriptome 
profiles of two cohorts of metastatic NBLs using RNA sequencing.  
First, I studied changes in splicing pattern in a cohort of 29 patients. V-Myc Avian 
Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog (MYCN) amplified 
NBLs showed a distinct splicing pattern affecting multiple cancer hallmarks. Six splicing 
factors have altered expression patterns in MYCN-amplified tumors and cell lines, and 
binding motifs for these factors were significantly enriched in differentially-spliced 
genes. ChIP-seq analysis showed direct binding of MYCN to promoter regions of 
splicing factors PTBP1 and HNRNPA1, demonstrating that MYCN regulates splicing by 
directly regulating expression of key splicing factors. Furthermore, high expression of  
PTBP1 and HNRNPA1 was significantly associated with poor overall survival of stage 4  
	 viii 
NBL patients (p≤0.05). Knocking down PTBP1, HNRNPA1 and their downstream target  
PKM2, a pro-tumor-growth isoform, resulted in repression of NBL cell growth. 
Second, I used whole transcriptome sequencing in a cohort of 150 patients to 
assess expressed mutations, fusion genes, and gene expression including long non-coding 
genes to provide clinically-relevant classification and to offer insights into NBL tumor 
biology. Twenty-four genes including ALK, ATRX and MYCN were recurrently mutated 
in NBL transcriptomes. In-frame FOXR1 fusions were detected in 4 samples, including 3 
cases or 14% of stage 4S NBLs. Unsupervised gene expression analysis revealed four 
molecular subgroups. MYCN and tumor microenvironment were the primary 
discriminating signatures in these molecular subgroups. Fifty-eight percent of MYCN-not-
amplified samples showed high MYCN signatures, which were potentially contributed by 
various genomic events such as MYCN activating mutations and FOXR1 fusions. High 
MYCN signature was significantly associated with poor overall survival in MYCN-not-
amplified tumors (p=0.0017). In addition, the tumor microenvironment including stromal 
and immune cell infiltration significantly contributed to the NBL transcriptional 
landscape and tumor progression. 
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CHAPTER ONE: INTRODUCTION, BACKGROUND, RATIONALE 
Why is transcriptome important 
 The central dogma of molecular biology describes the flow of genetic information 
from genomic DNA to RNA to protein within a biological system. In early 2003, The 
Human Genome Project estimated there are 23,000 protein-coding genes representing 
~1.2% of the human genome sequence (2004; consortium, 2001). While the existence of 
noncoding RNAs such as transfer RNAs (tRNAs), ribosomal RNAs (rRNAs), small 
nucleolar RNAs (snoRNAs), and microRNAs were noted at the time, not until a decade 
later,  the Encyclopedia of DNA Elements (ENCODE) project reported in 2012 that 62% 
of the human genome are reproducibly represented in RNA molecules (>200 nucleotides) 
based on a conservative threshold (consortium, 2012). Although many of the functions of 
these transcripts are currently unclear, the transcriptome is an essential component in 
human biology. Considering the additional contributions from alternative splicing, 
variable 3’ and 5’UTRs, RNA editing, and secondary/tertiary structure varieties, the 
diversity of RNA molecules could certainly multiply exponentially compared to the 
number of genomic loci. 
 Accordingly, RNA has inched its way into the spotlight to improve our 
understanding of cancer biology and for development of novel biomarkers and targeted 
therapies for personalized cancer medicine. Gene expression profiling has been used for 
diagnosis and predicting outcome in cancer patients since microarray technology first 
became popular (Khan et al., 2001; van't Veer and Bernards, 2008). However, the 
emergence of whole transcriptome sequencing technology has provided us with 
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unprecedented opportunities to profile RNA molecules at single nucleotide resolution 
without prior sequence knowledge. For the past 5 years, thousands of tumor 
transcriptomes have been generated. By mining the massive data generated, we are closer 
to the understanding of the functions of various transcripts and to develop RNA-based 
biomarkers and novel therapies for personalized cancer medicine. 
Focus of whole transcriptome sequencing analysis 
The major goals of whole transcriptome sequencing analysis are to elucidate the 
structure and sequence of transcripts and to determine transcript expression. Aberrant 
gene expression, including protein-coding genes, non-coding transcripts, fusion genes, 
viral-integrated genes, allelic imbalance expression, and pseudogenes can all contribute 
to tumor initiation, progression and metastasis (Figure 1.1).  In my thesis, areas of focus 
include non-coding transcripts and fusion genes analysis.  
Long Non-coding RNAs (lncRNAs, >200 nt) including tRNAs, rRNAs, small 
nuclear RNAs, and small nucleolar RNAs were once thought “housekeeping” RNAs. 
They are emerging as a new category of non-coding RNAs that carry important functions 
in cancer (Gutschner and Diederichs, 2012b; Spizzo et al., 2012b). Many of the lncRNAs 
have not been explored or even annotated, thus RNA-seq is an ideal tool to systematically 
capture transcribed lncRNAs. For example, one study discovered 121 novel prostate 
cancer associated non-coding RNAs, and found one of them, PCAT-1, to be implicated in 
prostate cancer progression (Prensner et al., 2011). This report showed that lncRNAs 
express in a tissue- and disease-specific manner, hence systematically profiling lncRNA 
is important to understand disease biology, and to develop lncRNA based biomarkers.  
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Abnormal fusion genes caused by chromosomal rearrangements often play key 
roles in tumor initiation and progression. Historically, highly-recurrent fusion gene events 
were identified in cancers with cytogenetic techniques (Douglass et al., 1987; Nowell, 
1962). Due to the poor resolution of these techniques, identification of the fusion partners 
and their fusion products is not a trivial task. RNA-seq is used to systematically discover 
genome-wide fusion events with single nucleotide resolution of fusion break points, 
which can be used in diagnosis or targeted clinical intervention for cancers (Maher et al., 
2009a; Maher et al., 2009b; Roberts et al., 2012; Steidl et al., 2011; Zhao et al., 2009). In 
one study investigators performed RNA-seq in high risk acute lymphoblastic leukemia 
with a Ph –like gene expression signature but lacking the BCR-ABL fusion gene and 
found fusion events of genes involving ABL1, JAK2, PDGFRB, CRLF2, and EPOR. 
They reported that several of these genomic events result in transformation that was 
attenuated with tyrosine kinase inhibitors, thus indicating that these patients may be 
treated with targeted therapy in future trials (Roberts et al., 2012). Therefore, RNA-seq 
can be an effective method to comprehensively examine genome-wide gene fusions, 
including novel events with low recurrences in tumors.  In addition to fusion gene events 
caused by genomic rearrangement, RNA-seq can also detect trans-splicing and read-
through transcripts, which were recently found to be important in cancer development 
(Rickman et al., 2009; Zhang et al., 2012). Such events are difficult to detect by 
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traditional cytogenetic techniques or DNA sequencing.
 
Figure 1.1 RNA-seq specific analyses on gene expression and post- transcriptional regulation. 
The structure and expression level of a transcript are not only controlled by 
transcription-regulating programs, but also by post-transcriptional modifications 
including splicing, polyadenylation and RNA-editing (Figure 1.1). Because RNA-seq 
provides single nucleotide resolution, these post-transcriptional mechanisms can be 
systematically explored with RNA-seq data. Another area of  focus in my thesis is the 
analysis of alternative splicing, the most prevalent post-transcriptional RNA processing 
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event which affects 95% of all human multi-exon genes (Pan et al., 2008). Spliceosomes 
catalyze the splicing process by recognizing splice sites located at exon-intron 
boundaries. In some cancers, genomic mutations disrupt important splice sites that result 
in aberrant splicing, which can cause insertion, deletion or frame shifts in the amino acid 
sequence. Moreover, splicing factors that bind to specific pre-mRNA binding motifs 
regulate splicing patterns in a tissue- and disease- specific manner (Cheung et al., 2008; 
Langer et al., 2010; Sveen et al., 2011; Venables et al., 2009). Changes of splicing factors 
are shown to be important contributors during normal tissue development such as 
epithelial-mesenchymal transition (Shapiro et al., 2011), as well as tumorigenesis, such as 
tumor cell motility (Gardina et al., 2006), metastasis (Bemmo et al., 2010; Dutertre et al., 
2010), metabolism (Guo et al., 2011), and proliferation (Misquitta-Ali et al., 2011). 
In addition, DNA sequencing technology has been used extensively to detect 
cancer somatic variations and indels. Most somatic mutations are discovered by DNA 
sequencing rather than RNA-seq studies. However, RNA-seq can be used to complement 
DNA sequencing to distinguish a “driver” mutation event from “passenger” mutations 
(Figure 1.2). DNA sequencing can identify hundreds if not thousands of genomic variants 
in a single cancer genome; therefore distinguishing “driver” genomic variant that causes a 
selective growth or survival advantage to the tumor is challenging. Researchers can 
narrow down potential driver mutations by examining transcriptome expression and 
evaluating if the genomic variation is expressed in the RNAs (Jun S. Wei, 2013). Cancer 
driver genes can promote tumorigenesis or development by gain or loss of their normal 
functions. The genomic mechanisms underlying the gain or loss of function can be copy 
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number change, structural or sequence mutations, which can all have impacts on the 
expression of affected genes.  
 
Figure 1.2 Flowchart for genomic aberration validations and functional predictions using RNA-seq data for 
elucidating biology and directing therapy. These DNA changes can result in changes to the transcript. 
Additionally, RNA-seq may reveal tractable changes due to alternative splicing or RNA editing. These changes 
can be linked to pathways or drugs for therapeutic intervention. Adapted from Principles and Practices of 
Pediatric Oncology (Pizzo and Poplack, 2011). Tractable genomic alterations can occur either in germ line or in 
somatic cells. Alterations may result from copy number variations such as whole chromosome gains (losses are 
usually incompatible with life) or segmental changes. Constitutional chromosomal rearrangements have been 
observed in patients with cancer. These rearrangements can result in truncation of a protein, expression of a 
gene under the control of an alternative promoter or the production of a chimeric or novel fusion protein not 
normally found in nature. Single nucleotide variations (SNV) or polymorphisms (SNP) are associated or causal 
to an increased predisposition to cancer. These variations may be in the promoter regions leading to over 
expression or suppression or may be within the protein coding regions leading to cancer syndromes. Other 
constitutional alterations that predispose to cancer include paternal segmental isodisomy or in a cancer copy 
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neutral loss of heterozygosity where there is no net loss of DNA but uniparental disomy with only one parental 
chromosome or region present in two copies. Epigenetic alteration such as silencing of genes by methylation is 
an increasingly important mechanism of oncogenesis.  
Neuroblastoma 
Neuroblastoma (NBL) is a pediatric malignancy derived from the developing 
sympathetic nervous system. It is the most common extra-cranial solid tumor in children,  
representing 8% to 10% of all childhood cancers (Philip A. Pizzo, 2011). In addition, 
NBL is the most common cancer diagnosed in infancy, with the median age diagnosed at 
19 months (London et al., 2005). Metastatic stage 4 Neuroblastoma is characterized by its 
clinically heterogeneous outcome. Despite improvement in the survival rate with 
multimodal chemo- and immunotherapy, high morbidity and mortality is still 
considerable for patients with metastatic disease. Less than half of patients older than 12 
months with stage 4 disease survive, whereas those with MYCN-amplification (MYCN-A; 
20-25% of all NBL) have an even worse outcome (Cohn et al., 2009). MYCN 
amplification status is the only genetic marker that is routinely included in clinical 
practice. However, stage 4S patients (2-5% of all NBL (Benard et al., 2008) ), who are 
younger than 12 months of age, have a characteristic pattern of metastasis with rapid 
tumor growth followed by spontaneous regression and a good overall survival rate of 
>90% (Maris, 2010; Pizzo and Poplack, 2011). 
Familial cases are estimated to be accounted for 1-2% of all NBL cases (London 
et al., 2005).  Germline mutations in the tyrosine kinase domain of the ALK gene are 
reported to be activating mutations by familial linkage studies (George et al., 2008; 
Janoueix-Lerosey et al., 2008). In addition, germline mutations in the homeodomain 
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PHOX2B gene have been detected with familial NBL cases (Mosse et al., 2004; Trochet 
et al., 2004). It is estimated that ALK and PHOX2B account for ~80% of all familial NBL 
cases (Brodeur and Bagatell, 2014).  
Recent large-scale sequencing studies by our group and others (Cheung et al., 
2012; Molenaar et al., 2012; Pugh et al., 2013a; Sausen et al., 2013) have discovered only 
a few novel recurrent somatic mutations in NBL, with MYCN-amplification (20-25%) 
and ALK mutations (8-10%) still being the most recurrent gene alteration events. 
Moreover, ATRX is found to be mutated in 44% of tumors from the adolescent and young 
adult groups (Cheung et al., 2012). However, among all NBL patients, ATRX is only 
found to be mutated in less than 3% of patients along with five other genes, PTPN11, 
NRAS, MYCN, ARID1A and ARID1B (Pugh et al., 2013b; Sausen et al., 2013). 
RNA sequencing technology 
The three most common RNA-seq platforms are Roche's 454, Illumina's HiSeq 
and Life Technology's SOLiD system. All of these platforms generate millions of short 
sequencing reads per sequencing run (100-1000bp). Liu et al. (Liu et al., 2012) compared 
the performance of these platforms in terms of sequencing mechanism, components and 
cost, and application, providing scientists a useful guideline for choosing the most 
suitable platform for their research project. More recently, smaller sequencers with lower 
throughput but faster turnaround time have been introduced for clinical applications. Life 
Technology 's Ion Torrent Proton and Illumina's MiSeq instruments shorten the run time 
from weeks to a day or less for a typical RNA-seq experiment (Liu et al., 2012; Quail et 
al., 2012). Moreover, direct RNA sequencing technologies such as Helicoscope 
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developed by Helicos Biosciences eliminate the error-prone cDNA synthesis step 
(Ozsolak et al., 2009). Third generation sequencing, led by PacBio and Oxford Nanopore, 
promises direct single-molecule sequencing without requiring PCR amplification steps. 
With a length of more than 1000bp, these third generation sequencing technologies have 
the potential to generate long reads spanning full-length RNA molecules (Schadt et al., 
2010). Here, I used RNA-seq to study two cohorts of metastatic NBLs. The first cohort 
contains 29 NBL transcriptomes sequenced with Life Technology’s SOLiD system using 
50bp single end read. The detailed analysis of this cohort is mainly in chapter 3. The 
second cohort contains 150 NBL transcriptomes sequenced with Illumina’s Hiseq system 
using 100bp paired-end reads. The detailed analysis about this cohort is mainly in 
chapters 4 and 5.  
Moreover, two different library preparation strategies were used in these cohorts 
of NBL transcriptome sequencing projects. The first cohort of 29 NBLs transcriptomes 
was processed using rRNA depletion. This method aims to exclude rRNA and tRNAs, 
which comprise the majority of total RNA in a cell. rRNA depletion retains LncRNA 
lacking polyadenylated (poly(A)) -tails. This RNA species has emerged as an important 
player in tumorigenesis (Gutschner and Diederichs, 2012a; Spizzo et al., 2012a). Low 
RNA quality can result in poor efficiency of ribosomal RNA removal, leaving a large 
portion of the rRNA in the libraries. In addition, pre-mRNA, intermediate products, and 
partially degraded RNA can also be detected in rRNA depleted libraries. These molecules 
can provide additional information or noise in RNA-seq data. The second cohort contains 
150 NBLs transcriptome processed using poly(A) enrichment. A poly(A)-enriched library 
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is made by priming with poly-dT primers. This method highly enriches for mature 
mRNA with poly(A) tails. However, the downside to this approach is the loss of non-
polyadenylated RNA which may also carry out important functions in biological systems 
(Yang et al., 2011). Additionally, poly (A) RNA enrichment may result in 3’ bias (Figure 
1.3), which can be more prominent in samples with RNA degradation.  
 
Figure 1.3 Gene coverage of polyA enriched RNA-seq from samples with high and low RNA integrity number 
(RIN). For sample with RIN number of 8.7, homogeneous coverage between transcription start site and 3’UTR 
is observed. However for sample with RIN of 6.4, coverage is biased towards the 3’ UTR.  
Summary 
Previous DNA sequencing studies characterizing the genetic basis of NBL had 
revealed a very low somatic mutation burden and surprisingly low number of recurrent 
somatic mutated genes compared to solid adult tumors. In order to identify novel 
molecular therapeutic targets and understand the biology of high-risk NBL, we 
investigated whole transcriptome profiles of tumors using RNA sequencing on two 
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cohorts of high-risk NBL (Table 1.1). Chapter two describes the materials and methods 
used in the subsequent analysis. Chapter three focuses on splicing control, the most 
important post-transcriptional regulation of NBL cohort 1. Chapter four focus on the 
expressed somatic mutation, chimera transcript analysis, and gene expression landscape 
of NBL cohort 2. Finally, chapter five describes the ongoing project and collaboration on 
long non-coding transcript analysis of NBL cohort 2.  
 
Chapters 
Number 
of 
samples 
Sequencing 
platform 
Read 
length Paired-end 
Library 
preparation 
NBL 
cohort 1 2, 3 29 SOLiD 50 No rRNA depletion 
NBL 
cohort 2 2, 4, 5 150 Illumina 100 Yes polyA enriched 
 
Table 1.1 Summary of transcriptome sequencing projects on two NBL patients cohort. The following 
chapters will focus on specific analyses on NBL cohort 1 or cohort 2.  
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CHAPTER TWO: MATERIALS AND METHODS 
Project one 
RNA isolation and whole transcriptome library construction  
Total RNA was extracted, RNA-seq libraries were made and sequenced as 
previously described (Wei et al., 2013; Wei and Khan, 2002). The integrity of total RNA 
was evaluated using an Agilent BioAnalyzer 2100 (Agilent, Palo Alto, CA), and only 
RNAs with RNA Integrity Number (RIN) greater than 6.0 were used in this study. 
RNA-seq reads alignment, differential expression and splicing analysis 
First, 50 base nucleotide reads were filtered against a database of rRNA, tRNA, 
repetitive regions, and adapter sequences.  The remaining reads were aligned to the 
reference human genome (hg 18) and spice junctions database using Bioscope v1.2 (ABI, 
Foster City, CA), with mapping mismatch penalty of -2.0. Reads mapped to more than 10 
different genomic locations were discarded. 
We used Cufflinks 1.0.3 (Trapnell et al., 2010) for isoform abundance estimation 
based on Refseq hg18 for isoform sequences. Abundances in fragments per kilobase of 
exon per million fragments mapped (FPKM) were calculated for each annotated Refseq 
isoform. Isoforms expressed in ≥ 3 samples (n=29628) were included for principle 
component analysis using Partek software version 6.5 (Partek Inc., St. Louis, MO, USA). 
The cumulative proportion of the first 3 principle components was 34.6%. Proportion of 
variance: PC#1=13.3%, PC#2=12.3%, PC#3=9.02%.  
Cuffdiff module of Cufflinks 1.0.3(Trapnell et al., 2010) was used to evaluate 
differential expression and differential splicing “TSS-genes”. In differential expression 
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analysis, Cuffdiff compares the log ratio of “TSS-gene” expression in two conditions. 
Variance included the variability among biological replicates and uncertainty in the 
isoform expression estimation itself. “TSS-genes” with Benjamini-Hochberg FDR <0.25 
and fold change >2 were selected as significantly differentially expressed. In differential 
splicing analysis, Jensen-Shannon divergence (JS; 0 ≤ JS ≤ 1) was calculated for each 
cancer subtype by Cuffdiff, and a one-sided t-test was performed, with the null 
hypothesis that no alternative splicing causes relative abundances of isoform expression 
change. Differentially spliced “TSS-genes” were selected based on Benjamini-Hochberg 
FDR<0.05, and Jenson-Shannon divergence √𝐽𝑆 >0.2.  
Multivariate Analysis of Transcript Splicing (MATS) 3.0.8 (Shen et al., 2012) 
was used to determine differential splicing events in IMR5 cell line with PTBP1 and 
HNRNPA1 knockdown. Significant events were calculated using reads falling into 
Refseq annotated exon and splicing junctions. Differential splicing genes with FDR 
<0.05, and exon-inclusion difference >0.1 were used for downstream gene ontology 
analysis.  
Gene ontology analysis 
Gene ontology (GO) analysis was performed and visualized using Cytoscape 
(Cline et al., 2007) and ClueGO (Bindea et al., 2009). Gene symbols for DEG and DSG 
lists were inputted into the ClueGO.  Enriched GO terms in biological process were 
calculated based on right-side hypergeometric test with Benjamini-Hochberg adjusted p-
value<0.05. Enriched GO terms were grouped in networks based on their shared genes 
with GO term connection using ClueGO.  
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Splicing motif enrichment analysis 
Exactly 200 nt upstream and downstream intron sequences of differentially 
spliced exons between 4S and MYCN-A subtypes were analyzed for enriched motifs.  
Oligo-analysis module of Regulatory Sequence Analysis Tools (Thomas-Chollier et al., 
2008) (RSAT) was used for motif enrichment analysis. Second order Markov chain 
model was used for background model. P-value of over-representation of the motif 
occurrence and adjusted E-value were calculated as described by Helden et al (van 
Helden et al., 1998).  
Exon microarray hybridization and analysis  
We used Affymetrix Human Exon 1.0 array to measure the exon expression level 
of tumor samples. Ribosomal RNA was removed from total RNA using a RiboMinus 
Transcriptome Isolation Kit (Human/Mouse) and processed to generate the labeled 
targets using an Affymetrix GeneChip WT Sense Target Labeling and Control Reagents. 
After hybridization of the labeled targets to the probes, the array was stained and scanned 
as per manufacturer’s instructions. The probe-level analysis was performed using 
R/Bioconductor packages: aroma.affymetrix, biomaRt and Genomegraphs with the 
workflow described by Rodrigo-Domingo et al (Rodrigo-Domingo et al., 2013). 
Luciferase reporters under PTBP1 or HNRNPA1 promoter 
Luciferase reporter constructs under wild-type (pGL3-A1p) or mutant 
(pGL3A1pMu) HNRNPA1 promoter were obtained from Dr. Manley (David et al. 
(2010). Human PTBP1 promoter between genomic sequences 
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GTGCTTTCTATCCTGCTGGC and GACAGCTGCCCGAACAAC (chr11:797698+798124; 
hg19) was cloned into the pGL3-enhancer vector (Promega, Madison, WI) between 
the XhoI and HindIII restriction sites. Two-base inversion mutations were 
introduced to both E-box sites within the PTBP1 promoter by mutagenesis to 
generate the mutant form of the reporter (GenScript, Piscataway, NJ). All PTBP1 
reporter vectors were verified by Sanger sequencing. Luciferase reporters were 
transfected into SK-N-AS cells with a -glactosidase control plasmid using 
Lipofectamine 2000 according to the manufacturer’s protocol (Life Technologies, 
Carlsbad, CA). A MYCN expression vector under a CMV promoter was obtained from 
Origen (Rockville, MD).  Luciferase activities were measured as described previously 
(Wei et al., 2008). 
 
Cell culture, RNAi and western blot  
NBL cell line MYCN-3 with a tetracycline-controlled MYCN expression 
construct was cultured and induced at 9 hours as described by Wei et al (Wei et al., 
2008). IMR32 were cultured in EMEM, IMR5 and SK-N-AS were cultured in RPMI-
1640 (Quality Biological) supplemented with 10% fetal bovine serum, 2 mM L-
glutamine, 100 units/mL penicillin, and 100 g/mL streptomycin at 37˚C in 5% CO2. 
Cell lines were routinely checked for mycoplasma using the MycoAlert Mycoplasma 
Detection Kit (Lonza, Walkersville, MD). 
a. MYCN knockdown experiments 
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Non-silencing AllStars Negative Control siRNA (Qiagen, Valencia, CA) was 
used as negative control. siRNA was transfected into NBL cells by using Nucleofector 
(Amaxa Biosystems, Gaithersburg, MD) solution L following the manufacturer’s 
protocol. IMR32 cells were washed and collected into cold PBS at 48 hours post-
transfection, and the cell pellets were either used for protein or RNA extraction. Total 
protein lysates were prepared by re-suspending cells in RIPA buffer containing Halt 
Protease/Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific, Waltham, MA) and 
EDTA. After extraction, suspensions were centrifuged for 10 min at 14,000 rcf at 4 ˚C 
and the protein supernatant was collected and quantified using a Bradford protein assay 
(Sigma-Aldrich, St. Louis, MO). We used two different MYCN siRNAs purchased from 
Qiagen (SI00076293, Hs_MYCN_2 and SI00076307, Hs_MYCN_4, Valencia, CA).  
b. PTBP1, and HNRNPA1 knockdown experiments 
Reverse transfection was done using Lipofectamine RNAiMAX reagent (Life 
Technologies, Carlsbad, CA). In a clear bottom 6-well plate (Corning, Tewksbury, MA), 
2 mL of Opti-MEM (Life Technologies, Carlsbad, CA) was dispensed into each well 
with 10-20 µL of Lipofectamine RNAiMAX and a final concentration of 20nM for each 
siRNA. All siRNAs were previously described (Chen et al., 2012; Goldberg and Sharp, 
2012) and AllStars Hs Cell Death Control siRNA (Qiagen, Valencia, CA) was used as a 
positive control. All siRNAs were diluted in nuclease-free water (Life Technologies, 
Carlsbad, CA). The siRNA and Lipofectamine RNAiMAX was allowed to complex for 
30-45 minutes in the well at room temperature. Then 2 mL of IMR5 or SK-N-AS cells in 
20% FBS was seeded into each well so that the cells would reach 80% confluency after 
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48-72 hours. Confluence was monitored over time using the IncuCyte (Essen Bioscience, 
Ann Arbor, MI). Each data point is an average of confluence taken from 16 images. 
Confluence and cell number is assumed to be linear when cell morphology stays the same 
and full confluence is not achieved.  SiRNA sequences targeting PTBP1 and HNRNPA1 
were listed in Supplementary Table 2.1.  
 
PTBP1 GCCUCAACGUCAAGUACAA 
HNRNPA1 CAGCUGAGGAAGCUCUUCA 
PKM2_1 AGGCAGAGGCUGCCAUCUA 
PKM2_2 CCAUAAUCGUCCUCACCAA 
 
Table 2.1. SiRNA sense sequences targeting PTBP1, HNRNPA1 and PKM2 
 
After 48-72 hours siRNA transfection, cells were lysed in 50-100 µL of RIPA 
buffer (Thermo Fisher Scientific, Waltham, MA) with 1% Halt Protease and Phosphatase 
Inhibitor Cocktail (Thermo Fisher Scientific, Waltham, MA). Protein was quantified by 
BCA assay (Thermo Fisher Scientific, Waltham, MA) and reduced in 2X SDS Protein 
Gel Loading Solution (Quality Biological, Gaithersburg, MD) containing 5% β-
mercaptoethanol (Sigma-Aldrich, St. Louis, MO). Samples were boiled at 95°C for 10 
minutes and then 5-10 µg of protein was loaded into 4-12% Tris-Glycine polyacrylamide 
gels (Life Technologies, Carlsbad, CA). The resolved protein was transferred to 0.2 µm 
nitrocellulose membranes using the iBlot (Life Technologies, Carlsbad, CA). Membranes 
were blocked in room temperature with 5% nonfat dry milk in TBS (Corning, 
Tewksbury, MA) with 0.1% Tween-20 for one hour and subsequently probed overnight 
in 5% BSA (Sigma Aldrich, St. Louis, MO) in TBST at 4°C in the following antibodies: 
  
 
18 
PTBP1 (1:1,000 Cell Signaling Technology #8776, Danvers, MA), hnRNPA1 (1:1,000 
Cell Signaling Technology #8443, Danvers, MA), and β-actin (1:10,000 Sigma Aldrich 
#A1978, St. Louis, MO). Membranes were washed 3 times with TBST and then 
incubated in HRP-conjugated goat anti-mouse (1:10,000 Santa Cruz Biotechnology sc-
2005, Dallas, TX) or goat anti-rabbit (1:10,000 Santa Cruz Biotechnology sc-2004, 
Dallas, TX) secondary antibodies in 1% nonfat dry milk in TBST for 1 hour at room 
temperature. Membranes were washed 3 times in TBST again and then bound antibodies 
were detected using SuperSignal (Thermo Fisher Scientific, Waltham, MA) and 
chemiluminescence was detected on CL-XPosure Film (Thermo Fisher Scientific, 
Waltham, MA).  
RT-qPCR  
Quantitative RT-PCR was performed using Taqman assays (Life Technologies, 
Carlsbad, CA) on a Fluidigm system as previously described (Stauffer et al., 2012). 
Briefly, cDNA was generated from 200 ng of RNA using reverse transcription. Then 
PCR was carried out on a 48x48 dynamic array using BioMark HD real-time PCR system 
(Fluidigm, San Francisco, CA). Triplicates were performed for each gene for every 
sample, and average threshold cycle (Ct) numbers were calculated. Gene expression 
levels were represented by normalized Ct (-∆Ct) against GAPDH.  Primer catalog 
number and customized primer sequences used to amplify cDNAs are listed in Table 2.2. 
gene Taqman catalog number 
RBFOX3 Hs01370653_m1 
CELF2 Hs00272516_m1 
CELF6 Hs00907140_m1 
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HNRNPA1 Hs01656228_s1 
RBFOX1 Hs00251554_m1 
PTBP1 Hs00917042_g1 
 
Table 2.2. RT-PCR primers catalog number or sequences.   
Chromatin Immunoprecipitation sequencing (ChIP-seq) 
ChIP-seq experiment was performed on MYCN3 cell line either untreated (low 
MYCN) or treated with doxycyclin (high MYCN) as previously described (Shohet et al., 
2011). Reads were mapped against human reference genome and stored using Genboree 
discovery platform (Shohet et al., 2011). The mapped ChIP-seq database was further 
visualized using UCSC genome browser (HG19) for MYCN binding at gene promoters 
or intergenic regions and E-box motifs at binding sites.  Peaks were called using MACS 
(Zhang et al., 2008) software, and followed by HOMER for genome feature enrichment 
analysis and GO term annotation. 
Data access 
Sequence data used for this study are available at dbGaP under the accession 
number phs000868.v1.p1 
 
Project two 
Patients and samples 
 Tumor samples from 150 high risk or stage 4S patients were selected for RNA-
sequencing. Moreover, 139 NBLs which had whole genome sequencing (WGS) had 
whole exome sequencing (WES) or whole genome sequencing (WGS) of tumor/normal 
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pairs through the Therapeutically Applicable Research to Generate Effective Treatments 
(TARGET) initiative. 
 
RNA-seq library construction and sequencing 
The integrity of total RNA was evaluated using an Agilent BioAnalyzer 2100 
(Agilent, Palo Alto, CA), and only RNAs with RIN greater than 6.0 were used in this 
study. Poly(A) enrichment method was used for RNA-seq library construction. One 
hundred and one bp paired-end reads were sequenced using Illumina HiSeq platform.  
Read mapping and gene quantification 
 RNA-seq reads were generated in fastq format, and mapped to Human genome 
hg19 using TOPHAT2 (Kim et al., 2013a). Cufflinks was used for gene and transcript 
level quantification (Trapnell et al., 2012). ENSEMBL database was used for gene and 
transcript model references.  
Expressed mutation analysis 
 One hundred and thirty-nine samples with DNA sequencing data available were 
used for expressed mutation analysis. We required at least 10 reads covering the 
particular site to call it expressed. Additionally, we required at least 3 variant allele reads 
to confirm the expression of the somatic mutations.  
Fusion gene analysis 
 We used defuse (McPherson et al., 2011) and TOPHAT (Kim et al., 2013a) for 
fusion gene analysis. Defuse results were further filtered by 1) break point spanning reads 
>20; 2) break point homology < 20; 3) mean map count <20; 4) fusion sequence 
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homology genome/est/est island/cdna <0.9; 5) read through events; 6) fusion events 
reported in 200 normal samples. 7) minimum number of 3 supporting reads. TOPHAT 
was further filtered by minimum number of 3 supporting reads.  
Consensus clustering 
Consensus  clustering (Monti et al., 2003) was used for unsupervised clustering. 
K=1,2,….10 were assessed, and K=4 was selected for the final clustering. R package 
Consensus Cluster Plus was used to implement consensus clustering and visualizations 
(Wilkerson and Hayes, 2010).  
Single sample gene-set enrichment analysis 
 We used single-sample gene set enrichment analysis (ssGSEA) (Barbie et al., 
2009; Subramanian et al., 2005) to evaluate gene set enrichment score using single 
sample expression profile. Additionally, we used R package ESTIMATE (which is based 
on ssGSEA analysis) to infer tumor purity and stromal and immune cell fractions 
(Yoshihara et al., 2013).  
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CHAPTER THREE: GENOME-WIDE ANALYSIS OF SPLICING PATTERNS 
AND UPSTREAM REGULATORS IN HIGH-RISK NEUROBLASTOMA 
TUMORS 
Introduction 
Recent large-scale sequencing studies by our group and others (Cheung et al., 
2012; Molenaar et al., 2012; Pugh et al., 2013a; Sausen et al., 2013) have discovered only 
a few novel recurrent somatic mutations in NBL, with MYCN-amplification and ALK 
mutations being the most recurrent gene alteration events (Deyell and Attiyeh, 2011).  
Despite MYCN’s well-studied roles in transcription, the effects of MYCN on RNA 
splicing have not been extensively studied. Previous expression studies by our group 
using exon microarrays demonstrated that tumors with and without MYCN-amplification 
have different spicing patterns (Guo et al., 2011).  However, the mechanisms underlying 
the MYCN-associated splicing signature have not been investigated.  
For my thesis, we took advantage of massively parallel RNA sequencing to 
investigate the pattern of transcription and splicing of genes controlled by MYCN.  We 
identified six splicing factors important in MYCN-A tumors and demonstrated that 
MYCN is responsible for a gene splicing pattern by directly controlling these splicing 
factors especially PTBP1 and HNRNPA1 in MYCN-A samples. Furthermore, we 
observed that high PTBP1 and HNRNPA1 expression is associated with poor survival in 
high-risk NBL patients (p≤0.05). Finally we demonstrated that knocking down of PTBP1 
and HNRNPA1, or their downstream target, the pro-tumor-growth isoform PKM2, 
resulted in suppressed proliferation in a MYCN-amplified neuroblastoma cell line.  
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Samples and sequencing statistics 
In order to investigate the role of MYCN on transcription and splicing control of 
transcripts, we performed massively parallel RNA sequencing (RNA-seq) on 29 stage 4 
NBL tumors (10 MYCN amplified (MYCN-A), 10 MYCN-not-amplified (MYCN-NA), and 
9 4S; Table 3.1). The median number of reads mapped to the genome was 103.7 million 
per sample (Figure 3.1A), with 35.5% to the coding bases and UTRs, and 1.5% to the 
exon-exon junctions (Figure 3.1B).  We used random priming for construction of RNA-
seq libraries for an even coverage of genes from their 5’ to 3’ ends to ensure unbiased 
detection of different transcripts of a gene (Figure 3.1C). 
 
Figure 3.1. Sequencing statistics of 29 NB samples. (A) Box-plot representing number of mapped reads per 
sample. The box signifies the upper and lower quartiles, and the median number of mapped reads per sample is 
103.7 million.  (B) The pie chart represents the distribution of mapped regions. The median percentage mapped 
to exon-exon junctions, coding region and UTRs, introns, and intergenic regions are 1.51%, 35.5%, 47.3% and 
15.7% respectively.  (C) Box-plot diagram showing a homogeneous coverage from 5' to 3' of the RNA molecule.  
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Sample 
label 
Age at 
diagnosis 
Tumor 
stage 
MYCN 
amplification  
clinical 
outcome 
Sample 
subgroup 
NB106 0.03 4s No Alive 4S 
NB107 0.65 4s No Alive 4S 
NB12 0.10 4s No Alive 4S 
NB236 0.33 4s No Alive 4S 
NB239 0.67 4s No Alive 4S 
NB40 0.2 4s No Alive 4S 
NB62 0.00 4s No Alive 4S 
NB82 0.10 4s No Alive 4S 
NB84 0.40 4s No Alive 4S 
NB21 5.20 4 Yes Dead MYCN-A 
NB265 1.83 4 Yes Dead MYCN-A 
NB266 2.00 4 Yes Dead MYCN-A 
NB27 10.50 4 Yes Dead MYCN-A 
NB278 1.67 4 Yes Dead MYCN-A 
NB541 9.58 4 Yes Dead MYCN-A 
NB545 3.36 4 Yes Dead MYCN-A 
NB547 1.54 4 Yes Dead MYCN-A 
NB581 1.58 4 Yes Dead MYCN-A 
NB583 2.72 4 Yes Dead MYCN-A 
NB205 3.92 4 No Dead MYCN-NA 
NB206 2.67 4 No Dead MYCN-NA 
NB207 4.42 4 No Dead MYCN-NA 
NB209 1.58 4 No Dead MYCN-NA 
NB210 2.50 4 No Dead MYCN-NA 
NB283 5.44 4 No Dead MYCN-NA 
NB536 3.06 4 No Dead MYCN-NA 
NB540 3.39 4 No Dead MYCN-NA 
NB586 4.44 4 No Dead MYCN-NA 
NB8 4.60 4 No Dead MYCN-NA 
      Table 3.1. Twenty-nine tumors in NBL cohort 1. The table shows age at diagnosis, tumor stage, MYCN 
amplification status, survival info, and sample subgroup assignment in this study.  
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NBL subgroups exhibit differential expression pattern at transcript level 
The expression of each transcript isoform is the combined result of both 
transcription and splicing programs (Figure 3.2). To distinguish the transcription versus 
splicing of isoform expression, we first grouped transcript isoforms transcribed from the 
same transcription starting site (TSS) as “TSS-genes”, which are controlled by the same 
transcriptional machinery. Thus the sum of isoforms expressed from the same "TSS-
gene" reflects transcription control. By contrast, differences in expression ratios of 
isoforms spliced from the same “TSS-gene” are the results of the splicing control 
(Germann et al., 2012). There were 29628 transcripts detected in ≥3 samples representing 
20486 TSS-genes. Of 5424 TSS-genes having more than 1 isoform, the average number 
of isoforms for each TSS-gene was 2.6± 1.1 standard deviation (SD).   
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Figure S3.2. Flow chart of analytical method to investigate transcriptional and splicing regulation separately. 
Isoforms with same TSS were grouped into TSS genes. In this example, both TSS gene1 and TSS gene2 had 2 
isoforms. For TSS gene1, the total expression of isoform1 and isoform2 did not change in two cancer subtypes, 
but the ratios of isoform 1 and isoform 2 changed (from 18:2 to 10:10); thus TSS gene1 was affected by splicing 
regulation. On the contrary, the total expression of two isoforms for TSS gene2 changed (from 40 to 200), while 
the ratios of two isoforms did not change (3:1), so TSS gene2 was affected by the transcriptional program. 
Transcriptional factors and splicing factors controlled each of the regulatory programs separately. 
In order to examine if there is any specific isoform expression pattern among the 
stage 4 NBL subgroups, we next performed a principle component analysis (PCA) using 
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all 29628 transcript isoforms. The complete separation of 4S and MYCN-A clusters 
demonstrated distinct expression patterns of gene expression between the two groups 
(Figure 3.3A). Interestingly, MYCN-NA samples fall between the 4S and MYCN-A 
clusters suggesting varied  transcript expression for this subgroup probably due to their 
heterogeneous nature of these tumors (Guo et al., 2011; Molenaar et al., 2012). 
Differential transcription and splicing among NBL tumors 
To dissect out the transcription and splicing controls of the transcript expression, 
we first examined the transcription control by differential expression analysis of "TSS-
genes". The 4S and MYCN-A group comparison resulted in the highest number of 
differentially expressed genes (860 DEGs), reflecting the diverse gene expression 
between 4S and MYCN-A tumors. In contrast, fewer “TSS-genes” were differentially 
expressed between MYCN-NA and 4S group (124 DEGs), or between MYCN-NA and 
MYCN-A group (93 DEGs, Figure 3.3B), possibly due to the heterogeneity among 
MYCN-NA samples.   
We next examined the splicing program by differential splicing analysis using 5424 
“TSS-genes” which have more than one annotated isoform detected in ≥ 3 samples. The 
largest difference was again seen in the 4S and MYCN-A groups comparison, with 460 
differentially spliced “TSS-genes” (DSGs); whereas there were 308 and 332 DSGs in 4S 
vs. MYCN-NA, and MYCN-NA vs. MYCN-A comparisons respectively (Figure 3.3B). 
Notably, very few "TSS-genes" overlapped between DEGs and DSGs in their respective 
comparisons, indicating that only a small portion of "TSS-genes" were differentially 
regulated by both transcription and splicing programs.  
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Figure 3.3. Transcriptional and splicing programs control isoform expression. A. PCA analysis of all transcripts 
shows separation of NBL subgroups. First three principle components were calculated using isoform expressions 
of 29 primary tumors. Red spheres represent MYCN-A samples; blue MYCN-NA samples; and green 4S 
samples. B. Differentially expressed genes (DEGs) and differentially spliced genes (DSGs) among stage 4 NBL 
subgroups. Numbers of DEGs and DSGs are plotted in pair-wise comparisons of three NBL tumor subtypes.  
In order to characterize tumors with the most extreme clinical outcomes, and to 
avoid reduced statistical power caused by large sample-to-sample variance among 
MYCN-NA tumors, we used 4S tumors as control to perform gene ontology (GO) 
enrichment analysis for both DEGs and DSGs in MYCN-A tumors. DEGs up-regulated in 
the MYCN-A tumors were enriched with genes involved in the cell cycle and DNA 
metabolism (Supplementary Figure 3.4A),  whereas DSGs in MYCN-A tumors were  
enriched with genes of cell adhesion, cell cycle, immune system process, development, 
and programmed cell death (Supplementary Figure 3.4B). Thus, our data strongly suggest 
that transcription and splicing processes control different biological processes specific to 
their respective biology in NBL tumors.  
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Figure 3.4 Enriched gene ontology groups for DEGs and DSGs. The overview pie chart shows the proportion 
that represents each group from the total. A. Enriched GO term groups for DEGs up-regulated in MYCN-A 
tumors compared to 4S tumors. B. Enriched GO term groups for DSGs in 4S vs. MYCN-A tumors pair-wise 
comparison. 
Transcription factors activated in 4S and MYCN-A tumors 
To identify the key transcription factors activated in subgroups, we performed the 
transcription factor analysis using gene expression networks observed in our dataset 
(Ingenuity®Systems, www.ingenuity.com). We found four transcription factors notably 
activated in tumors with MYCN amplification (Z-score>3, p<0.001) (Figure 3.5A, Table 
3.2). Remarkably, three of them are well characterized oncogenes for NBL 
(MYCN/MYC, E2F1, and FOXM1).(Engelmann and Putzer, 2012; Westermark et al., 
2011; Wierstra and Alves, 2007) In contrast, transcription factors activated in the 
subgroup 4S were TP53, CDKN2A and RB1 (Z-score>3, p<0.001; Figure 3.5B, Table 
3.2), are classic tumor suppressors.(Chinnam and Goodrich, 2011; Gogolin et al., 2013; 
Omura-Minamisawa et al., 2001) Therefore, our data demonstrate that the activation of 
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both oncogenic programs in MYCN-A tumors and tumor suppressor programs in 4S 
tumors are under the transcription control of these key factors. 
Transcription 
Factor 
Activated 
in group 
Regulation 
in Z-score 
p-value of 
overlap 
# of 
DEG 
# of DEG 
direction 
consistent with 
TF activation 
MYC/MYCN MYCN-A 4.56 1.10E-04 46 29 
E2F1 MYCN-A 4.5 2.73E-14 46 26 
TBX2 MYCN-A 4.31 3.17E-10 18 18 
FOXM1 MYCN-A 3.14 1.24E-10 16 13 
TP53 4S 5.81 1.02E-17 95 61 
CDKN2A 4S 4.89 1.42E-14 34 31 
RB1 4S 3.18 5.95E-17 41 18 
 
Table 3.2. Activated transcription factors in MYCN-A and 4S samples. Based on transcriptional program 
controlled DEGs, 4 transcription factors MYC, E2F1, TBX2 and FOXM1 are activated in MYCN-A subgroup 
(Z-score>3, p<0.001).  Transcription factors TP53, CDKN2A and RB1 are activated in 4S subgroup (Z-score>3, 
p<0.001). P-value represents significance of overlapped genes between differentially expressed genes to 
transcription factor’s known targets. Z-score inferred activation states is based on comparison with regulation 
directions observed in NBL tumors to the predicted directions based on literature. 
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Figure 3.5. Activated transcription factors in MYCN-A and 4S tumors. A. Networks show activated transcription 
factors as hubs in MYCN-A tumors and their regulated genes as nodes. B. Networks show activated 
transcription factors in 4S tumors as hubs and their regulated genes as nodes. 
Splicing factors that are differentially expressed in MYCN-A tumors 
To identify the splicing factors responsible for the splicing signatures in these 
tumors, we searched for genes associated with RNA splicing (n=318; Gene Ontology: 
0008380) and also differentially expressed in the MYCN-A tumors. Six splicing factors 
RBFOX1, RBFOX3, CELF2, CELF6, PTBP1 and HNRNPA1 showed significant 
differential expression in MYCN-A tumors (Figure 3.6A). Except for RBFOX3 (the 
probes for which were not represented on the array), we were able to validate our 
findings in an independent cohort consisting of 151 stage 4 NBL tumors using exon array 
(http://target.nci.nih.gov/dataMatrix/TARGET_DataMatrix.html) (Figure 3.6B). Thus, 
these splicing factors are likely responsible for the differential splicing pattern seen in the 
MYCN-A tumors. 
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Figure 3.6. Differentially expressed splicing factors in MYCN-A tumors. A. Six splicing factors RBFOX1, 
RBFOX3, CELF2, CELF6, PTBP1 and HNRNPA1 are differentially expressed between tumor subtype MYCN-A 
to 4S and/or MYCN-NA. Box-plot diagrams show the minimum and maximum values with the quartiles’ 
expression levels in samples of each NBL subgroup. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. B. Expression 
of splicing factors in stage4 NBL tumors (n=150). Expressions of RBFOX1, CELF2, CELF6, PTBP1, and 
HNRNPA1 are significantly different in an independent cohort of 150 stage 4 NBL samples (p≤0.01). Outliers 
(1.5 times inter-quartile distance larger than 75th percentiles or smaller than 25th percentiles) were represented 
by dots.  
In addition, we performed an in-silico analysis for the enrichment of the splicing 
factors’ binding motif sequences in the flanking introns of the differential spliced exons 
for DSGs. We found that the binding motif of the CELF family and PTBP1 family were 
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significantly enriched in the adjacent intron in MYCN-A tumors (FDR<1.0E-3, Figure 
3.7). There are more than 100 different binding motifs reported for HNRNPA1 in the 
literature (Piva et al., 2012), as a result, no consensus sequence was meaningful for the 
HNRNPA1 binding motif analysis. The enrichment of splice binding sites upstream or 
downstream of alternatively spliced exons provide compelling evidence that splicing 
factors of the PTBP1, and CELF family have important roles in controlling the splicing 
program in NBLs.  
 
Figure 3.7 200nt upstream and downstream intronic regions of alternatively spliced exons in various in vitro and 
in vivo conditions were tested for splicing factors binding motif sequences enrichment. -log10 (FDR) value was 
shown here and used for heatmap plot. UPI: upstream intron region. DNI: downstream intron region.  
MYCN directly regulates PTBP1and HNRNPA1 in NBL 
To experimentally examine if MYCN regulates the expression of these six 
splicing factors, we perturbed MYCN protein level and monitored the change of 
expression levels of these splicing factors using a MYCN inducible cell line (MYCN-3) 
(Slack et al., 2005; Wei et al., 2008), and knockdown of MYCN in a MYCN-amplified 
NBL cell line (IMR-32) using 2 independent siRNAs.  Among the six splicing factors, 
PTBP1 and HNRNPA1 showed positive correlation with MYCN expression (Figure 
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3.8A, B), whereas the other four splicing factors showed expression change only in one 
of the MYCN perturbation experiments (data not shown); indicating that PTBP1 and 
HNRNPA1 are likely the direct downstream targets of MYCN. 
To test if MYCN directly controls these two splicing factors, we examined the 
binding of MYCN to the genomic loci of these splicing factors using chromatin 
immunoprecipitation sequencing (ChIP-seq) on a MYCN inducible cell line (MYCN-3) 
(Shohet et al., 2011). Of the 12754 peaks identified by ChIP-seq, 3584 (28.1%) were 
localized in the promoter regions which were significantly enriched from the genome 
(2.4% of human genome are of promoter, p<0.001). Genes with peaks in promoter region 
were selected for biological process/pathway enrichment. Interestingly, RNA processing, 
spliceosome and mRNA splicing pathways were among the top enriched biological 
process/pathways using Gene Ontology, KEGG and REACTOME databases, suggesting 
the regulatory role of MYCN in mRNA splicing program in NBL (Table 3.3). At the loci 
of PTBP1 and HNRNPA1 genes near their promoter region, there are enriched MYCN 
binding signals, indicating the expression of these two splicing factors is directly 
controlled by MYCN (Figure 3.8C, D; left panels). This observation is consistent with a 
previous study reporting up-regulation of PTBP1 and HNRNPA1 by MYC (David et al., 
2010). However, we did not detect MYCN binding at the loci of RBFOX3, RBFOX1, 
CELF2, or CELF6 (Figure 3.9A-D), suggesting MYCN indirectly regulates the 
expression of these factors. Finally, in order to confirm that  MYCN directly regulates the 
expression of splicing factor PTBP1 and HNRNPA1, we performed the luciferase reporter 
assays in a MYCN-NA neuroblastoma cell line SK-N-AS using expression vectors under 
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the control of PTBP1 or HNRNPA1 promoter. Luciferase assays clearly demonstrated 
that wild-type promoter reporters were responsive to the overexpression of ectopic 
MYCN in a dose-dependent manner; whereas promoters with mutant E-boxes 
significantly lost responsiveness to the ectopic expression of MYCN (Figure 3.8 C, D; 
right panels). Therefore, we concluded that PTBP1 or HNRNPA1 are under the direct 
transcriptional control of MYCN. 
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Figure 3.8 MYCN directly regulates splicing factors PTBP1 and HNRNPA1. A. MYCN perturbation alters the 
level of splicing factor expression. Vann diagram shows the positively-correlated splicing factor expression with 
MYCN induction or MYCN siRNAs knockdown. B. Real-time RT-PCR validation of the differentially expressed 
splicing factors PTBP1 and HNRNPA1 upon MYCN induction and MYCN siRNAs knockdown. Mean 
expression of genes is plotted. Error bars represent standard deviation. ChIP-seq (left panels) show MYCN 
binding to the promoter regions (red tracks) of PTBP1 (C) and HNRNPA1 (D). Actin antibody was used as a 
negative control (green tracks). Luciferase reporter assays (right panels) demonstrate that wild-type PTBP1 
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(pGL3-PTBP1, C) and HNRNPA1 (pGL3-A1p,D) promoters are directly controlled by MYCN; whereas mutant 
forms of these promoters (Mu) greatly attenuate the effect of MYCN. 
DATABASE Term_ID TERM P-value 
GeneOntology GO:0006396 RNA processing 2.58E-18 
Biological 
process GO:0016071 mRNA metabolic process 3.50E-18 
 
GO:0010605 
negative regulation of 
macromolecule metabolic process 1.01E-16 
 
GO:0007049 cell cycle 1.20E-15 
 
GO:0009892 
negative regulation of metabolic 
process 2.72E-15 
KEGG hsa03013 RNA transport 2.01E-08 
 
hsa04110 Cell cycle 2.05E-08 
 
hsa03040 Spliceosome 2.90E-07 
 
hsa04120 Ubiquitin mediated proteolysis 5.17E-07 
 
hsa05203 Viral carcinogenesis 2.04E-06 
REACTOME REACT_115566 Cell Cycle 2.12E-10 
 
REACT_121061 
Transcriptional activity of 
SMAD2/SMAD3:SMAD4 
heterotrimer 2.87E-10 
 
REACT_152 Cell Cycle, Mitotic 7.20E-10 
 
REACT_125 
Processing of Capped Intron-
Containing Pre-mRNA 1.21E-08 
 
REACT_467 mRNA Splicing - Major Pathway 2.02E-08 
Table 3.3. Top enriched biological process/pathways of MYCN-bound promoter genes using Gene Ontology, 
KEGG and REACTOME databases. 
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Figure 3.9 ChIP-seq analysis of MYCN binding to splicing factors. No ChIP-seq peaks observed on A. RBFOX3 
B.RBFOX1 C. CELF2 D.CELF6  gene region (red track). Actin antibody was used as a negative control (green 
track).   
Expression of splicing factors predicts clinical outcomes in NBL patients 
To evaluate the clinical relevance of the splicing signature in high-risk NBLs 
mediated by these splicing factors, we examined whether the expression of splicing 
factors predict patient survival. Indeed, high expression of PTBP1 and 
HNRNPA1predicted poor survival in a cohort of stage 4 NBLs 
(http://target.nci.nih.gov/dataMatrix/TARGET_DataMatrix.html, n=150, Figure 3.10 A-
B).  In order to avoid the confounding effect of MYCN-amplification on survival, we 
further performed the survival analysis in patients with only MYCN-NA stage 4 tumors 
(n=103). Interestingly high expression of PTBP1 still predicts poor outcomes for this 
group of patients (p=0.03, Figure 3.10C), suggesting its important function of this 
splicing factor in neuroblastoma. PTBP1 has been reported to be regulated by MYC, a 
MYCN homolog, in NIH-3T3 cells (David et al., 2010), and high MYC pathway activity 
has been associated with poor outcome of MYCN-NA NBL (Fredlund et al., 2008). 
Indeed, the expression of PTBP1 mRNA was positively correlated with that of MYC 
(Figure 3.10D, p=0.05), but not with MYCN (Figure 3.10D, p=0.4) in these MYCN-NA 
tumors. Remarkably, the differentially expressed genes between PTBP1-high and 
PTBP1-low samples were significantly enriched with the MYC direct targets in a gene 
set enrichment analysis (Figure 3.11 upper panel, gene set: 
DANG_REGULATED_BY_MYC_UP (Zeller et al., 2003), FDR<0.001; Figure 3.11 
lower panel, gene set: PID_MYC_ACTIVPATHWAY (Schaefer et al., 2009), 
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FDR<0.001), supporting the adverse effects of MYC in these poor outcome patients 
without MYCN amplification. 
 
Figure 3.10 High expression of PTBP1 and HNRNPA1 are correlated with worse overall survival in stage 4 NBL 
patients. High expression of A. PTBP1 and B. HNRNPA1 predicts overall survival in all 150 stage 4 NBL 
patients (log-rank test; p=0.0095 and p=0.05 respectively). C. PTBP1 expression still predict outcome for 103 
stage 4 MYCN-NA NBL patients (log-rank test, p=0.03). D. MYC is differentially expressed between PTBP1-high 
and PTBP1-low stage 4 MYCN-NA NBLs (p=0.05, mean±SD). 
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Figure 3.11. Gene set enrichment analysis (GSEA) plots of ranked genes of PTBP1-high samples compared to 
PTBP1-low samples show significant enrichment of MYC signatures (FDR<0.001). 
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Knockdown PTBP1 and HNRNPA1 results in growth suppression of NBL 
cells 
To test if splicing factor PTBP1 and HNRNPA1 are important for MYCN driven 
neuroblastoma cells, we knocked them down using RNA interference in neuroblastoma 
cell lines. Combined knockdown of PTBP1 and HNRNPA1 suppressed proliferation of 
MYCN-amplified IMR5 cells (Figure 3.12A); whereas the same combined knockdown 
had a much milder suppression of the growth in MYCN-not-amplified SK-N-AS cells 
(Figure 3.12B). In addition, RNA-seq showed that 199 genes displayed differentially 
splicing upon PTBP1 and HNRNPA1 knocking down in IMR5 cells (FDR<0.05, exon 
inclusion difference >0.1), with exon skipping event to be the most frequent event 
(Figure 3.13). Interestingly the differentially splicing genes were enriched in neuron 
development and cell cycle process (Gene Ontology analysis, FDR<0.01, Figure 3.14), 
indicating the splicing program may modulate these two important cell functions in this 
neuroblastoma cell. 
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Figure 3.12. Knockdown of splicing factors PTBP1 and HNRNPA1 suppresses the growth of MYCN-amplified 
IMR5 and SK-N-AS cell line. A. Left panel: IMR5 cell proliferation was monitored over 72 hours after double 
knockdown of splicing factors PTBP1 and HNRNPA1 using siRNAs (n=2, mean±SEM). Right panel:Western 
blots show effective knockdown of PTBP1 and HNRNPA1 at protein level. B. Left panel: SK-N-AS cell 
proliferation was monitored over 72 hours after double knockdown of splicing factors PTBP1 and HNRNPA1 
using siRNAs (n=2, mean±SEM). Right panel:Western blots show effective knockdown of PTBP1 and 
HNRNPA1 at protein level. 
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Figure 3.13. Splicing events observed upon PTBP1 and HNRNPA1 knockdown. Number of each category of 
differential splicing events upon PTBP1 and HNRNPA1 knockdown: skipped exon (SE), mutually exclusive 
exons (MXE), alternative 5’ splice site (A5SS), alternative 3’ splice sites (A3SS), retained intron (RI).  
 
Figure 3.14. Neural development and cell cycle process are the main functions of the differentially spliced genes 
after the knockdown of splicing factors. RNA-seq was used to profile gene expression after knockdown of the 
two splicing factors. Gene ontology networks show enriched gene ontology of differentially spliced genes 
detected upon PTBP1 and HNRNPA1 knockdown. 
 
PKM splicing is a major target of splicing of PTBP1 and HNRNPA1  
The top most differentially spliced and highly expressed genes upon PTBP1 and 
HNRNPA1 knockdown was pyruvate kinase gene (PKM) (Figure 3.15A). Switching 
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from PKM1 expressed commonly in differentiated tissues to its oncofetal counterpart 
PKM2 often occurs in actively growing human cancers (Wong et al., 2015), and splicing 
factors in the PTB and HNRNP families are reported to mediate the PKM isoform 
switching (Clower et al., 2010). We found that PKM showed a significant switch from 
exon10 (PKM2) to exon9 (PKM1) usage (FDR<1E-13) followed by knockdown of the 
both splicing factors (Figure 3.15B-C).  It is also one of the most differentially spliced 
DSGs in the stage 4 MYCN-A tumors. In addition, PKM exon10/exon9 ratio is correlated 
with the combined expression of PTBP1 and HNRNPA1 in NBL tumors (Figure 3.16, 
cor=0.42, p=9.0E-8), as well as the ratio was significantly higher in stage 4 MYCN-A 
tumors compared to MYCN-NA tumors (Figure 3.17 A, p=0.0026). Furthermore, the 
exon10/9 ratio of PKM also significantly associated with worse outcome in all 
neuroblastoma (p=0.005; Figure 3.17B) and in stage 4 MYCN-NA tumors (p=0.001; 
Figure 3.17). This is in keeping with high expression of the tumorigenic isoform PKM2 
which promotes tumor-favoring aerobic glycolysis in cancer including neuroblastoma 
(David et al., 2010; Guo et al., 2011).   
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Figure 3.15. Knockdown of PTBP1 and HNRNPA1 affect PKM splicing A. PKM is the highest expressed gene in 
IMR5 cells among the differentially spliced genes. RNA-seq was performed on IMR5 transcriptome and 
differentially spliced genes are ranked from highest to the lowest expression. B. Sashimi plot shows RNA-seq 
tracks upon PTBP1 and HNRNPA1 knockdown. The height of peaks indicates the expression level of exons and 
curved lines represent exon-exon boundaries. C. RNA expression ratio of Exon10/Exon9 was altered by 
knockdown of splicing factors indicating isoform switch from PKM2 to PKM1. Western blot of PKM2 and total 
PKM upon PTBP1 and HNRNPA1 knockdown showed decreased PKM2 level. β-actin was used as a loading 
control. 
 
Figure 3.16. Expression of PTBP1 and HNRNPA1 and the ratio of PKM exon10/exon9 are positively correlated 
in NBL tumors (n=150). 
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Figure 3.17 PKM exon10./exon9 ratio in NBL tumors. A. Higher PKM exon 10/exon 9 ratios were observed in 
stage 4 MYCN-amplified tumors (n=150). B. PKM exon10/exon9 ratio significantly predicts overall survival in 
all 150 stage 4 NBL patients, and C. in 103 stage 4 MYCN-NA NBL patients (log-rank test, p=0.005, p=0.001). 
Suppression of PKM2 isoform leads to growth inhibition in MYCN-A cells 
Since MYCN-amplification is predicted to increase expression of PKM2 and is 
associated with adverse outcome, we used two validated siRNAs (Goldberg and Sharp, 
2012) that target exon 10 of PKM to specifically knockdown PKM2 isoform in IMR5 and 
SK-N-AS cells. Western blot confirmed that, while the level of total PKM was intact, 
PKM2 levels were significantly reduced for both NBL cell lines using two independent 
siRNAs (Figure 3.18A-B). Interestingly, knockdown of PKM2 expression suppressed 
proliferation of IMR5 cells (Figure 3.18A). However it had no significant effect on 
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MYCN-NA SK-N-AS cells (Figure 3.18B), suggesting MYCN-A cancer cells may be 
more sensitive to the suppression of PKM2. 
 
Figure 3.18 A. IMR5 cell proliferation was suppressed by specific knockdown PKM2. Cell growth was 
monitored over 48 hours after PKM2 and control siRNA transfections. Western blot demonstrated decreased 
PKM2 protein level after 48 hours of PKM2 and control siRNA transfection in IMR5 cell line. β-actin was used 
as a loading control. B. SK-N-AS cell was not affected by PKM2 knockdown. The proliferation was monitored 
over 48 hours after PKM2 and control siRNA transfections. Western blot showed a decreased PKM2 protein 
level after 48 hours of PKM2 and control siRNA transfection on SK-N-AS cell line. β-actin was used as a loading 
control. 
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Discussion 
Differential isoform expression had been difficult to study prior to the advent of 
massively parallel sequencing technologies. Single nucleotide resolution of RNA-seq 
reads allow mapping to specific transcription start sites and splicing boundaries, making 
it feasible to deconvolve transcriptional control and splicing regulation for individual 
transcripts on a genome wide scale. In this study, we examined the transcriptome of stage 
4 NBL tumors for the aberrations that would alter isoform expression. Our study is the 
first systematic attempt to examine the effects of splicing factors on transcript isoform 
expression in stage 4 NBL, which provides insight into how MYCN controls the 
expression of splicing factors, which in turn regulates a splicing signature at a genome-
wide level in neuroblastoma tumors. 
In agreement with a previous study on the NBL splicing program using exon 
arrays (Guo et al., 2011), we identify a splicing signature in MYCN-A tumors. Although 
the function of most of the spliced isoforms has not been elucidated, the differential 
spliced genes are enriched in biological processes such as programmed cell death and 
differentiation. Six splicing factors are found to be differentially expressed in MYCN-A 
tumors.  In particular, we find by ChIP-seq, gene expression analysis and luciferase 
reporter assays that MYCN potentially directly regulates the expression of the splicing 
factors PTBP1 and HNRNPA1. This finding is in keeping with the previous studies 
linking MYC to splicing factors PTBP1 and HNRNPA1 in HeLa cells and mouse 
embryonic fibroblast (David et al., 2010).  
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We found a significant association of high expression of PTBP1 and HNRNPA1 
with poor survival in stage 4 NBL patients, whereas PTBP1 expression showed the more 
significant difference in outcome.  Interestingly we found that high PTBP1 expression 
levels was associated with adverse outcome  in stage 4 MYCN-NA NBL patients, and 
global gene expression analysis revealed that the difference between the two clinical 
subgroups was associated with  a MYC signature. This indicates that even in stage 4 
MYCN-NA NBL patients adverse outcome may be driven by high MYC activity.   
We found that knockdown of the splicing factors PTBP1 and HNRNPA1 
suppressed the proliferation of a MYCN-A IMR5 cell line, as well as a MYCN-NA SK-N-
AS cell line albeit to a lesser extent, indicating that a further exploration is warranted to 
target these splicing factors as potential novel therapies for NBL patients. Differentially 
splicing genes upon PTBP1 and HNRNPA1 knockdown are enriched in neuron 
development and cell cycle processes, which is in line with known functions of these two 
splicing factors. Previous studies have showed that repressing PTBP1 expression 
enhances neuron differentiation (Ramos et al., 2015; Xue et al., 2013). Moreover, PTBP1 
is involved in aberrant splicing in glioblastoma and breast cancer (Ferrarese et al., 2014; 
Wen et al., 2015). Mutations in HNRNPA1 cause multisystem proteinopathy and ALS 
(Kim et al., 2013b), and the function of this gene is linked to muscle differentiation and 
cell survival (Huang et al., 2013; Yao et al., 2010). Similar to PTBP1, HNRNPA1 is up-
regulated in hepatocellular carcinoma and prostate cancer, which result in aberrant 
splicing in tumors (Chettouh et al., 2013; Nadiminty et al., 2015).  
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Furthermore, the most significantly differentially spliced and highly expressed 
genes upon PTBP1 and HNRNPA1 knockdown in IMR5 cells is pyruvate kinase (PKM). 
We observe a decreased expression of oncogenic exon10 (specific to the isoform PKM2), 
and an increased expression of exon9 (specific to the isoform PKM1) when repressing 
PTBP1 and HNRNPA1. PKM2 is a key regulator in cell metabolism by mediating 
glycolysis which favors cancer cell growth known as Warburg effect (Christofk et al., 
2008; Mazurek et al., 2005). It is known to be controlled by splicing factors PTBP1 and 
HNRNPA1 (Chen et al., 2010; David et al., 2010), and is up-regulated in various cancer 
types (Wong et al., 2015). Higher exon10/exon9 ratio is observed in MYCN-A tumors, 
and the high ratio of exon10/exon9 correlates with poor survival in stage 4 NBL patients. 
Knockdown of oncogenic isoform PKM2 suppressed growth of MYCN-A IMR5 cell line, 
but not MYCN-NA SK-NA-S cells up to 48 hours, suggesting MYCN-A neuroblastoma 
may be more vulnerable to inhibition of abnormal splicing program. One possibility to 
explain the muted effect of PKM2 knockdown on SK-NA-S cells is that hypoxia 
condition is required to influence cell proliferation by reduced PKM2-mediated 
glycolysis in fast growing SK-N-AS cells (Harris, 2002). Another possibility is that there 
are alternative glycolysis metabolic pathways, such as the one activated by PKM1 in 
PKM2 null breast cancer model (Israelsen et al., 2013), as suggested in recent studies 
(Cortes-Cros et al., 2013; Israelsen et al., 2013). Nevertheless, apoptosis is induced in 
multiple tumor cell lines and xenograft models using siRNAs targeting isoform-specific 
exon of PKM2 (Goldberg and Sharp, 2012). Additionally, multiple small molecule 
PKM2 activators, which induce PKM2 to obtain the similar enzymatic activity of PKM1, 
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show antitumor properties in vivo and in vitro in preclinical studies (Parnell et al., 2013; 
Warner et al., 2014). Taken together, targeting oncogenic isoform PKM2 is a potential 
therapeutic target in MYCN-A NBL patients.  
In summary, our RNA-seq study reveals a unique gene splicing signature driven 
by MYCN or MYC through key splicing factors in neuroblastoma. Our findings highlight 
the important role of MYCN in regulation of a splicing program in addition to their well-
known transcription regulation in cancer. Although the functions of many of the 
alternative spliced isoforms are not known, we show that MYCN is an upstream player of 
Warburg effect in the MYCN-PTBP1/HNRNPA1-PKM2 pathway. The identification of 
the key splicing factors and their downstream oncogenic isoforms in neuroblastoma may 
lead to novel therapies in these aggressive MYC or MYCN driven cancers.  
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CHAPTER FOUR: INTEGRATIVE ANALYSIS OF DNA AND RNA 
SEQUENCING IN HIGH-RISK METASTATIC NEUROBLASTOMA  
Introduction 
Despite improvement of survival rate with multimodal chemo- and 
immunotherapy, mortality and morbidity is still considerable for metastatic NBL patients. 
Previous DNA sequencing studies have characterized the genetic basis of the disease and 
revealed a very low somatic mutation burden and surprisingly few recurrently mutated 
somatic genes compared to adult solid tumors. In order to identify novel molecular 
therapeutic targets and understand the biology of high-risk neuroblastoma, I investigated 
transcriptome profiles of tumors from a cohort of metastatic neuroblastoma patients using 
RNA sequencing as an integral part of the Therapeutically Applicable Research to 
Generate Effective Treatments (TARGET) project. 
 I used whole transcriptome sequencing in the cohort of 150 NBL patients to 
assess the expressed mutations, fusion genes, and gene expression profiles to provide 
clinically-relevant classification and to offer insight into NBL tumor biology. Twenty-
four genes including ALK (9.4%), ATRX (2.2%) and MYCN (1.4%) were recurrently 
mutated in NBL transcriptomes in keeping with our previously published study. We 
found in- frame FOXR1 fusions in 4 samples, including 3 infant cases. Unsupervised 
analysis using consensus clustering revealed four molecular subgroups. MYCN and 
tumor microenvironment signatures were found to be altered in these NBL molecular 
subgroups. Cluster 1 samples had enriched MYCN signature compared to other clusters. 
Fifty-eight percent of MYCN-not-amplified samples showed high MYCN signature, 
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which were potentially contributed by various genomic events such as MYCN activating 
mutations, FOXR1 fusions, or NRAS mutations. High MYCN signature was significantly 
associated with poor overall survival in MYCN-not-amplified tumors (p=0.0017). In 
addition, tumor microenvironment including stromal and immune cell infiltration 
significantly contributed to NBL transcriptional landscape and tumor progression. 
Elevated stromal infiltration in cluster 3 samples activated cytokines and growth factors, 
contributing to the inflammatory signature. Both cluster 3 and cluster 4 samples had 
elevated immune infiltration. However, pro-tumor growth immune cell markers, 
including tumor associated macrophage and regulatory T cell markers (Tregs) were up-
regulated in cluster 3 samples; while tumor-killing immune cell markers, including 
cytotoxic T cell and B cell markers were up-regulated in cluster 4 samples. Moreover, 
pro-tumor growth marker and cytotoxic T cell marker predicted survival outcomes in 
stage 4 MYCN-NA samples with low MYCN signature. Interestingly, cluster 4 samples 
harbored a higher number of expressed SNVs compared to cluster 3 samples (p=0.04). 
As expressed SNVs are likely to be associated with neo-antigens expression which are 
known to activate tumor killing cytotoxic T cells, elevated cytotoxic immune cell 
signature in cluster 4 samples is likely caused by higher number of expressed SNVs.  
Samples and sequencing statistics 
We sequenced the whole transcriptome of 150 primary NBL tumors. 139 out of 
150 samples have matched DNA sequencing data by whole exome sequencing (WES) 
and/or whole genome sequencing (WGS) (Figure 4.1A). The majority of the samples are 
stage 4 MYCN-NA NBLs (n=97). Twenty-one samples are stage 4S NBLs, and the 
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remaining 32 samples are stage 4 MYCN-A NBLs (Figure 4.1B). 
 
Figure 4.1. NBL RNA-seq cohort. A. The Venn diagram showing how WTS samples (orange) overlap with WES 
(blue) and WGS (green) samples. B. Number of samples in 3 NBL subtypes: 4S, stage 4 MYCN-NA and stage 4 
MYCN-A. Stage 4S samples have better survival outcomes compared to stage 4 tumors (p=0.006).  
PolyA RNA was sequenced on Illumina HiSeq platform. 90% of samples have 
more than 100M reads generated, with the median number of 158 million reads per 
sample (Figure 4.2A).  On average, 86% of reads were mapped to human genome (hg19). 
Out of mapped reads, 89% were mapped uniquely, with 72.9% mapped continuously to 
human genome, 14.5% to splicing junctions and 1.6% to long range junctions (Figure 4.2 
B-C). Based on genes and transcripts annotated in the ENSEMBL GRCh37 build 71,  
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67% of reads cover the mRNA coding and UTR regions (34.5% and 32.7% respectively), 
13.3% and 19.5% of reads cover intron and intergenic regions respectively (Figure 4.2D).  
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Figure 4.2 PolyA+ libraries of 150 tumors sequenced using Illumina HiSeq platform.  A. total number of reads 
generated, B. mapping percentage, C. uniquely mapping percentage, and D. nucleotide coverage ratio based on 
gene structure for each sample. Out of 150 samples sequenced, 3 samples were sequenced with 1 sample per lane 
with version 3 chemistry; 32 samples were sequenced with 1 sample per lane with version 2 chemistry; 98 
samples were sequenced with 2 samples per lane with version 3 chemistry; and 17 samples were sequenced with 
4 samples per lane with version 3 chemistry. Ninety percent of samples (n=135) have over 100 million reads 
generated, with the other samples acquiring a throughput close to 100 million reads.  
Expressed mutational landscape of NBL 
 In order to identify potential oncogenes and targetable mutations, we performed 
mutational analysis in 139 samples (20 4S, 91 MYCN-NA and 28 MYCN-A samples) with 
DNA sequencing (WES (Pugh et al., 2013b), and/or WGS (data not published)) data 
available.  
I used RNA-seq data to look for somatic mutation sites reported by DNA 
sequencing analysis. The expressed mutational landscape is summarized in Figure 4.3A. 
Out of 1500 non-silent single nucleotide variants (SNVs) reported by DNA sequencing, 
66% or 990 nucleotide sites were expressed in RNA; 41% or 614 nucleotide sites had 
variant alleles expressed, and the other 25% or 510 nucleotide sites had only reference 
alleles expressed. The number of expressed SNVs ranged from 0 to 27 in the samples 
analyzed, with a median of 3 SNVs per sample. However, 4S samples had a significantly 
fewer expressed SNVs, as 16 out of 20 4S samples had no expressed mutations detected 
(Figure 4.3B). In addition, overall the patients who survived had the same number of 
expressed mutations as deceased patients (Figure 4.3B).  
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 Figure 4.3 Expressed mutational landscape for 139 NBL tumors. A. Mutational profiles for each NBL tumor 
with DNA sequencing data. Blue color represents variant detected in expressed genes. Orange represents only 
reference allele detected in expressed genes. Grey represents mutational sites not expressed in RNA. B. Left 
panel, comparison of the number of expressed SNVs between three NBL subgroups. 4S samples harbor 
significant fewer expressed mutations (t-test, p<0.0001). Right panel, comparison of the number of expressed 
SNVs between survived and deceased patients (t-test, p=0.95). For each group, median value was plotted as a red 
line. ****p<0.0001  
  In total, five hundred and seventy-six genes harbored non-silent expressed 
mutations, including all five genes with significant somatic mutation frequencies reported 
by WES, which are ALK, PTPN11, ATRX, MYCN and NRAS (Pugh et al., 2013b). By 
gene ontology, expressed mutated genes were enriched for genes involved in ATP 
binding (p=2.03E-7), protein localization (p=1.97E-5), microtubule cytoskeleton 
(p=3.55E-5), neuron differentiation (p=2.26E-4), chromatin modification (p=8.2E-3) and 
protein kinase activity (p=9.0E-3) (Figure 4.4A). In addition, numbers of samples with 
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mutations in each of the enriched ontology are shown in Figure 4.4B. MYCN-A samples 
and MYCN-NA samples had equal prevalence in mutations in five enriched ontologies. 
However, MYCN-A samples had higher prevalence of mutations in genes involved in 
microtubule cytoskeleton compared to MYCN-NA samples (67.9% vs 20.9%, Figure 
4.4B, p=1.1E-5).  
 
Figure 4.4 Enriched ontologies for genes with expressed mutations. A. Six ontologies showed significant 
enrichment for genes with expressed SNVs (p<0.01).  B. Number of tumors in each subtype harbored SNVs in 
genes with six enriched ontologies. * MYCN-A tumors have a significantly higher portion of samples mutated in 
microtubule cytoskeleton compared to MYCN-NA tumors (Fisher’s exact test, p=1.10E-5).  
Twenty-four genes were recurrently mutated, including known NBL pathogenic 
mutations in ALK (9.4%) and ATRX (2.2%). Many expressed mutations showed high 
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variant allele frequency (VAF>0.5) and/or high expression values (RPKM>30) (Figure 
4.5A). Moreover, besides ALK, ATRX, and MYCN, 15 out of the remaining 21 (71.4%) 
recurrently mutated  genes here were shown to be mutated in other types of tumors; RNA 
polymerase II gene POLR2A and ZNF292, RNA binding gene FXR1, cadherin gene 
FAT4, cell cycle gene STAG1, DNA repair gene REV3L, chromosomal modifier EP400, 
histone deacetylases interacted LRIF1, histone binding gene CDYL, MAPK signaling 
pathway gene MAP3K12, protein tyrosine phosphatase gene PTPRH, microtubule 
binding gene MACF1, neuron growth related gene TRIO and GPC2, and cytoplasmic p53 
anchor protein CUL9 (Figure 4.5A).  Similar to all genes with expressed mutations, 
recurrently mutated genes were enriched with genes involved in chromatin (p=0.0018), 
ATP binding (p=0.005) and protein kinase activity (p=0.013) (Figure 4.5B). 
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Figure 4.5 Twenty four recurrently expressed mutations in NBLs. Top, recurrent somatic alterations within 
expressed genes are ranked by frequency. Left, samples are ranked first by tumor subtypes, and then by the 
number of expressed mutations; blue, MYCN-NA samples; purple, MYCN-A samples; green, 4S sample. The 
color (light to dark blue) of the mark represents the variant allele frequency (VAF) with many mutations 
appearing to favor the mutant allele. The size of the circle is proportional to expression (reads per kilobase of 
transcript per million mapped reads (RPKM)). B. Gene Ontology analysis of the recurrently expressed 
mutations revealed enriched alterations in chromatin (p=0.0018), ATP binding (p=0.005), and protein kinase 
activity (p=0.013). Some tumors accumulate multiple mutations in the same pathway (light gray = 1 mutations 
involved in the ontology; dark gray = 2 or more mutations involved in the ontology). 
 For 990 nucleotide sites with adequate RNA reads coverage, I performed allele 
specific expression analysis, and found 14 genes with a significant preference for the 
mutant allele in the RNA (Figure 4.6A, ∆VAF>0.2 and FDR<0.05). It is interesting that 
among the 14 genes with preferential mutant allele expression, many are tumorigenesis 
  
 
65 
genes such as known NBL pathogenic gene MYCN, neurite growth and developmental 
gene NCAN, neuronal disease associated gene CC2D1A, cell migration gene IGTA3, 
splicing factor SF3B1, and tumorigenesis promoting growth factor TGFBR1. One more 
extreme case showed a TP53 p.R282W mutation in NB2014 tumor RNA with 0.58 VAF, 
while the tumor DNA VAF was merely 0.05 with adequate read coverage, hence filtered 
out in the DNA somatic mutation analysis (Figure 4.6B, upper panel). IGV viewer 
screenshots showed adequate coverage of RNA reads on this particular site (Figure 4.6B, 
lower panel). Further analysis showed that for this sample, the other four somatic 
mutations did not show preferred expression of mutant allele in the tumor RNA over 
tumor DNA (Figure 4.6C). It is possible that this TP53 p.R282W mutation was clonal, 
existing in one subclone that was enriched in the tissue used for RNA sequencing. The 
other possibility is that the wildtype TP53 gene was degraded in the tumor, resulting a 
lower copy of wildtype TP53 expression in the tumor RNA.  
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Figure 4.6 Preferential mutant allele expression in NBL transcriptome. A. Orange dots represent genes with 
preferred mutant allele expression in the RNA (fisher’s exact test, ∆VAF>0.2  and FDR<0.05,). B. Upper panel: 
reads and VAF for TP53 p.R282W site in germline DNA, tumor DNA and tumor RNA. Lower panel: IGV 
screenshot of TP53p.R282W site in tumor RNA sample. C. Compare mutant allele VAF for TP53p.R282W 
(purple triangle) to other four mutations (green triangles) in sample NB2014. Only TP53p.R282W showed 
preferential mutant allele expression.  
Fusion gene landscape of NBL 
 Next I performed fusion gene analysis in all 150 tumors. In order to filter out false 
positive calls and inconsequential translocation events, I used fusion genes detected in 
200 normal samples as negative control. After removing read-through transcription 
events, 915 fusion events were identified, with the median of 4 fusions per sample. In 
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particular, stage 4S samples harbored fewer fusions compared to stage 4 samples (Figure 
4.7A, p<0.05). Moreover, there was no significant difference in patient who survived or 
deceased (Figure 4.7B). Four hundred and fifty events (49.2%) were reported to be inter-
chromosomal; the remaining intra-chromosomal events were predicted to be the 
consequences of genomic deletion (n=181, 19.8%), inversion (n=150, 16.4%) and 
eversion (n=134, 14.6%). In addition, 123 fusion events were predicted to have 
breakpoints at exon boundaries, and only 52 fusion events preserved the open reading 
frames. Out of all fusion events reported, 17.5% or 160 events were characterized as 
chromosome 2 intra- chromosomal events, with many located at MYCN locus in MYCN-
A samples (Figure 4.8 C-D). NBAS and DDX1 were the most recurrent fused protein 
coding genes, with 14 and 13 samples harboring fusions affecting these two genes 
respectively.  This was in line with previous translocation rearrangement analysis of NBL 
samples based on WGS platform (Pugh et al., 2013b), reflecting the episomal model for 
MYCN amplified tumors (Storlazzi et al., 2010) .  
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Figure 4.7 Number of fusion events reported for NBLs. A. Stage 4S NBLs had fewer fusion events compared to 
stage 4 NBLs (t-test, 4S vs MYCN-A, p=0.03; 4S vs MYCN-NA, p=0.02). B. No significant difference in the 
number of fusion events for patients who survived or deceased (t-test, p=0.94). For each group, median value is 
plotted in red. *p<0.05. B. Left panel, inter-chromosome 2 fusion events of MYCN-A tumors. Right panel, Inter-
chromosome 2 fusion events of MYCN-NA tumors.  
 Two genes harbored in-frame fusions recurrently in this NBL cohort. Firstly two 
MYCN-A samples had in-frame ALK fusions (Figure 4.8A). In sample PAPEFE, the 
ITSN2 breakpoint was located at the 3’ end boundary of exon 14 (chr2: 24518532), while 
the ALK break point was located at the 5’ end boundary of exon 2 (chr2: 29940563), 
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resulting an in-frame ITSN2-ALK fusion with preserved ALK functional domains 
including two MAM domains, one low-density lipoprotein class A (LDL) domain and 
one kinase domain. Another complex pattern of multiple fusions was detected in the same 
sample. In this case, the same ITSN2 breakpoint was fused with the 5’ end boundary of a 
non-coding gene LINC00276’s second exon (chr2: 14457227). Moreover, the 3’ end 
boundary of the same LINC00276 exon was fused with ALK at the 5’ end boundary of 
exon 2 (chr2: 29940563), identical to the breakpoint of ITSN2-ALK fusion, resulting a 
new ITSN2-LINC00276-ALK fusion. Sample PATDXG also exhibited a complex 
translocation pattern. The most abundant transcript had an exon2-exon11 deletion, which 
were lacking two MAM domains (aa 264-427 and 480-626), and one LDL domain (aa 
453-471) in the extracellular domain of ALK. Two more transcripts fused to the 
intergenic region of FAM179A at ALK’s exon boundary or intron 11 boundary. The 
genomic locations of ALK and its fusion partners are plotted in Figure 4.8B. Interestingly, 
the expression level of ALK was significantly higher in the two samples with ALK 
fusions than in fusion negative samples (Figure 4.8C, p<0.0001).  
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Figure 4.8 ALK fusions in NBL tumors. A. Fusion structures in two MYCN-A samples NB2027 and NB2266. 
Transcript structure of fusion ITSN2-ALK, ITSN2-LIN00276-ALK, ALK(∆2-11), ALK-FAM179A are shown here. 
B. Genomic locations of ALK and its fusion partners. C. Expression of ALK gene in fusion positive and fusion 
negative samples. Samples with ALK fusions had a significantly higher ALK expression (p<0.0001). ALK log2 
(FPKM) values are plotted in red and purple for fusion-positive samples. ALK log2 (FPKM) values are plotted in 
blue for fusion-negative samples. The mean value is also plotted as a black line.  
Additionally, FOXR1 fusion was detected in four NBL samples. FOXR1 encodes 
a transcription factor in the helix-turn-helix forkhead box (FOX) family. It is located at 
11q23 region, which is commonly deleted in NBLs (Guo et al., 1999). Three out of four 
samples (PASPBZ, PASSWW, PARBAJ) harboring FOXR1 fusions are young infants, 
ranging from 8 to 63 days of age at the time of diagnosis. Although fusion partners were 
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different in four cases, the gene structures of FOXR1 fusions were very similar (Figure 
4.9A).  In all four cases, the 5’end of the fusion partner gene (C5orf4, DDX6, RP525 and 
MLL), including the first 1 or 2 exons,  fused to the 5’ end of FOXR1, either to the first 
exon prior to the start codon, or to the 5’ end upstream of FOXR1 gene. Consequently, 
the FOXR1 start codon and coding regions were all preserved in FOXR1 fusions. Three 
of the FOXR1 fusions were intra-chromosomal, with fusion partners adjacent to FOXR1 
in the 11q23 region. One other FOXR1 fusion was inter-chromosomal between chr5 to 
chr11 (Figure 4.9B).  Interestingly, the expression of FOXR1 was dramatically higher in 
samples with FOXR1 fusion, suggesting fusion events drive the elevated expression in 
NBLs (Figure 4.9C, p<0.0001).  
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Figure 4.9 FOXR1 fusions in NBL tumors. A. Fusion structures in four NBL samples. Transcript structure of 
fusion C5orf4-FOXR1, DDX6-FOXR1, RPS25-FOXR1, and MLL-FOXR1 are shown here. B. Genomic locations 
of FOXR1 and its fusion partners, three of which were adjacent to FOXR1 on chr11, and one was located on 
chr5. C. Expression of FOXR1 gene in fusion positive and fusion negative samples. Samples with FOXR1  fusions 
had a significantly higher expression (t-test, p<0.0001). FOXR1 log2 (FPKM) values are plotted in red for fusion-
positive samples. FOXR1 log2 (FPKM) values are plotted in blue for fusion-negative samples. ****p<0.0001 
Gene expression landscape of NBLs 
Consensus clustering (Monti et al., 2003) with K=2, 3, …10 of the  gene 
expression data using Ensembl gene annotation was performed to identify expression-
based clusters. The corresponding empirical cumulative distribution function (CDF) 
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showed the shape of the curve changed only slightly when K past 4 (Figure 4.10A, right 
panel). Subsequent consensus clustering (K=4) of 150 NBLs resulted in four distinct 
clusters, to which we refer as cluster 1, 2, 3, and 4 (Figure 4.10A left panel). In particular, 
cluster 1 comprised mostly stage 4 MYCN-A samples (16 out of 22). And cluster 2 
comprised mostly stage 4S samples (19 out of 30). Interestingly, 3 MYCN-NA patients 
less than 12 months old were in cluster 2, indicating that cluster 2 samples were 4S-like. 
MYCN-NA samples were the most heterogeneous subtypes of NBLs, spreading into all 
four clusters. Both cluster 3 and cluster 4 are comprised mostly stage 4 MYCN-NA 
samples (34 out of 50, and 46 out of 48 respectively, Figure 4.10B).    
To assess the clinical impact of the four clusters based on gene expression, I 
performed Kaplan-Meier survival analysis in all samples and stage 4 MYCN-NA samples 
only. Interestingly, survival outcomes were significantly different among the four clusters 
(Figure 4.10C, log-rank test p=0.002), with cluster 1 (n=22), which consist mainly of 
MYCN-A samples, presenting worst outcomes, while cluster 2 (n=30), consisting of 
mainly of 4S samples, presenting the best outcomes.  Consequently I categorized cluster 
1 samples as ultra-high-risk NBLs, and cluster 2 samples as 4S-like low risk NBLs. 
Likewise cluster 3 samples were also ultra-high-risk NBLs, with similar survival 
outcomes as cluster 1 samples. Cluster 4 samples had survival outcomes in between 
cluster 2 and cluster 3 samples, and were categorized as moderate risk NBLs. 
Interestingly, the overall survival outcomes were significantly different among stage 4 
MYCN-NA samples with four clusters (Figure 4.10D, log-rank test p=0.04), with cluster 
1 (number of MYCN-NA samples: n=6) presenting worse outcomes, and cluster 2 
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(number of MYCN-NA samples: n=11) presenting best outcomes. Additionally, cluster 3 
samples (n=34) had worse survival outcomes compared to cluster 4 samples (n=46).   
 
  
 
75 
Figure 4.10. Sample clusters based on gene expression. A. Consensus clustering matrix using gene expression 
profiles for 150 NBLs. Initially, cumulative distribution function was examined for K=1,2,…10. K=4 was 
selected for subsequent analysis. B. MYCN-amplification status (dark red: MYCN-A, pink: MYCN-NA), tumor 
subtypes (violet: stage 4, green: stage 4S), and age groups (light blue: <12 months, steel blue: ≥12months) in four 
clusters. C. Kaplan-Meier survival analysis for all samples in four consensus clusters showed stratified survival 
outcomes (log-ranked test, p=0.002). C. Kaplan-Meier survival analysis for stage 4 MYCN-NA samples showed 
stratified survival outcomes. (log-ranked test, p=0.04). Based on survival outcomes, cluster 1 and 3 patients were 
ultra-high risk, while cluster 2 and 4 patients were 4S-like low risk, and moderate risk respectively.  
MYCN signature in NBLs 
 Next I focused on potential molecular signatures and pathways underlying the 
four clusters. As ultra-high-risk cluster 1 samples were mostly MYCN-A samples, firstly 
I performed analysis to investigate functional MYCN signature. From an earlier study, 
mRNA levels of 157 genes represent MYCN signature in NBL tumors and cell lines 
independent of MYCN-amplification status (Valentijn et al., 2012). In this 157-gene set 
87 were upregulated by MYCN, and 70 were suppressed or down-regualted (Valentijn et 
al., 2012). Hierarchical clustering of the whole 150 NBL cohort using the 157-genes 
showed clear separation of the 87 up-regulated and 70 suppressed genes (Figure 4.11A). 
Across 150 NBLs, samples on the extreme right cluster represented higher MYCN 
signatures with increased expression of 87 genes induced by MYCN, and decreased 
expression of 70 genes repressed by MYCN (Figure 4.11A). Interestingly, ultra-high-risk 
cluster 1 samples showed highest activation of MYCN signature. In order to quantify 
MYCN signature for each sample, I calculated MYCN-signature scores by performing 
single-sample gene set-enrichment analysis (Barbie et al., 2009; Subramanian et al., 
2005; Verhaak et al., 2010). Cluster 1 samples (n=22) had the highest MYCN signature 
when compared to the other three clusters (Figure 4.11B, left panel for all samples, 
p<0.0001; right panel for stage 4 MYCN-NA samples, p<0.001). Interestingly, some 
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samples without MYCN-amplification showed elevated MYCN signature scores. It is 
possible that genomic events other than MYCN-amplification activated downstream 
MYCN-signature. Additionally, as reported previously (Fredlund et al., 2008), activation 
of MYC family proteins such as MYC or MYCL may contribute to downstream MYCN 
signature activation. Next, I explored the likelihood of several genetic mutations and 
expression aberrations that potentially elevate MYCN signature in MYCN-NA and 4S 
NBLs. 
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Figure 4.11 MYCN signature scores in NBLs. A. Hierachical clustering of 157 genes representing MYCN 
signature. Genes are clustered into two groups. One group is activated in MYCN signature (left horizontal, red 
lines), and the other group is repressed in MYCN signature (left horizontal, blue lines). Gene expression of 
samples with the highest functional MYCN signature was highlighted in green. B. MYCN signature score of all 
samples using single-sample gene set-enrichment analysis. Cluster 1 has higher MYCN signature scores 
compared to other clusters (t-test, p<0.0001). C. MYCN signature score of stage 4 MYCN-NA samples. Cluster 1 
  
 
78 
samples still has a higher MYCN signature score compared to other clusters (t-test, p<0.001). ***p<0.001, 
****p<0.0001.  
 MYCN p.P44L somatic mutation was reported in several types of tumors 
including neuroblastoma, and likely to be an activating mutation (Pugh et al., 2013b; 
Williams et al., 2015). As shown in Figure 4.12, two samples (1 stage 4 MYCN-NA, and 
1 stage 4S, in red) had an expressed MYCN p.P44L somatic mutation. Interestingly, while 
the MYCN mRNA expression of these two samples was lower than MYCN-A samples, the 
MYCN signature score was in the range of MYCN-A samples, indicating an activated 
MYCN signature through MYCN p.P44L somatic mutation.  
A DNA sequencing study found that NRAS and PTPN11 are frequently mutated 
in NBL (Pugh et al., 2013b). One stage 4 MYCN-NA sample harbors an expressed NRAS 
p.G13R mutation (Figure 4.12, in purple). NRAS p.G13R mutation was detected in 
various tumors types, including 117 samples in the catalogue of somatic mutations in 
cancer database (COSMIC) (Forbes et al., 2015). Moreover, NRAS mutation was shown 
to enhance MYC activities in melanocytes (Whitwam et al., 2007). Here in NBL, the 
sample with NRAS p.G13R mutation also showed elevated MYCN signature score, 
which was in the range of MYCN-A samples. Likewise, another stage 4 MYCN-NA 
sample harbors an expressed PTPN11 p.A72T mutation (Figure 4.12, in orange). 
PTPN11 p.A72T mutation was detected in various tumors types, including 34 samples in 
COSMIC database (Forbes et al., 2015).  A previous study showed that a gain-of-function 
PTPN11 mutation up-regulated MYC in mice lungs (Schneeberger et al., 2014). 
Although with lower MYCN expression compared to MYCN-A samples, the MYCN-NA 
sample with PTPN11 p.A72T mutation  which has been reported in many tumor types, 
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including 34 samples in the catalogue of somatic mutations of cancer database 
(COSMIC) (Forbes et al., 2015).   
As mentioned in the earlier section of this chapter, FOXR1 fusions drive the 
expression of transcription factor FOXR1 in four NBLs (two 4S NBLs, and two stage 4 
MYCN-NA NBLs, Figure 4.12, in blue). All four samples had low MYCN expression. 
Interestingly, all four samples, including two 4S samples, had high MYCN signature 
score in the range of MYCN-A samples. As noted, FOXR1 functionally replaces MYC 
and drives the proliferation of a neural crest stem cell line (Santo et al., 2012).  
Another stage 4 MYCN-NA NBL had a MYC-PVT1 fusion (Figure 4.12, in green) 
that is discussed in chapter five in detail. Both MYC and PVT1 expression were 
particularly high in this sample (chapter five, figure 5.3C). This sample also had an 
elevated MYCN signature score. Likewise, four samples with high MYC or MYCL 
expression (Figure 4.12, in pink and brown) showed high MYCN signature scores in the 
range of MYCN-A samples. A total of 7 samples in 4S and MYCN-NA subgroups with 
high MYCN expression are also shown here (Figure 4.12, in grey).  
To summarize, fifty-six or 58% of MYCN-NA NBLs displayed a MYCN 
signature score in the range of MYCN-A samples. Besides various genomic events and 
aberrant expression of MYC family proteins, it is possible that other mechanisms, such as 
MYCN protein stabilization, result in high MYCN signature scores in these samples. 
More details of the lncRNA PVT1 potential to stabilize MYC protein families will be 
discussed in chapter five.  
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Figure 4.12. Samples with low MYCN expression can have elevated MYCN signature scores. A. MYCN 
expression for NBLs. MYCN-A samples have significantly higher MYCN expression (t-test, p<0.0001). 
Log2(FPKM) value was plotted for each sample. B. MYCN signature scores for NBLs. Various MYCN-NA 
samples and several 4S samples had elevated MYCN signature scores in the range of MYCN-A NBLs. Samples 
with potential driving genetic mutations and expression aberrations were shown in color.  
 Next I explored the clinical impact of MYCN signature scores. Using the range of 
MYCN signature scores in MYCN-A samples as cutoff, eight 4S samples, and fifty-six 
MYCN-NA samples were categorized into high MYCN signature group. In line with a 
previous study (Valentijn et al., 2012), MYCN signature score is a better survival 
predictor compared to MYCN amplification or MYCN expression in NBLs (Figure 4.13). 
Intriguingly, 38% of 4S and 58% of MYCN-NA samples showed high MYCN signature, 
which was associated with poor outcome in NBLs (Figure 4.13 E-G). Consequently, the 
unfavorable outcomes of ultra-high-risk cluster 1 samples can be explained by the 
uniformly high MYCN signature.  
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Figure 4.13. Survival analysis of NBLs based on MYCN-amplification or signature, Kaplan-Meyer analysis 
showed that A. MYCN amplification was associated with worse outcome in all NBLs. (log-ranked test, p=0.042), 
and with a modest decrease in overall survival in stage 4 NBLs (log-ranked test, p=0.13). MYCN expression can 
not predict patient survival outcomes for C. all NBLs (log-ranked test, p=0.14) and D. stage 4 NBLs (log-ranked 
test, p=0.32). MYCN signature score can better predict patients survival outcomes in E. all samples (log-ranked 
test, p=0.0008), F. stage 4 samples (log-ranked test, p=0.0015), and G. stage 4 MYCN-NA samples (log-ranked 
test, p=0.0017).  
Tumor microenvironment among NBL clusters 
 Next, I investigated the molecular signature and pathways underling cluster 3 and 
cluster 4 samples, which comprise most of the MYCN-NA samples. Ultra-high-risk 
cluster 3 samples had worse survival outcomes compared to moderate-risk cluster 4 
samples (Figure 4.10 C-D). However, MYCN signature scores predicted similar MYCN 
downstream activation for the two clusters (Figure 4.11 B-C). Therefore, other 
mechanisms must contribute to the divergent prognosis of these samples. I investigated 
this idea further by performing differential expression analysis between cluster 3 and 4 
samples.  
 At FDR<0.05, I identified 4716 genes differentially expressed between cluster 3 
and cluster 4 samples, 3424 higher in cluster 3, and 1292 higher in cluster 4. A significant 
portion of differentially expressed genes (1655 out of 4716, 35.1%) were target 
molecules of cytokines and/or growth factors, of which 575 genes were the target 
molecule of cytokines only, 332 genes were the target molecules of growth factors only, 
and 748 genes were the target molecules of both cytokine and growth factor upstream 
regulators (Figure 4.14 A). Ingenuity pathway analysis predicted 23 growth factors and 
36 cytokines were overexpressed in cluster 3 compared to cluster 4, while only 1 
cytokine was overexpressed in cluster4 (Figure 4.14 B-C). Both cytokines and growth 
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factors indicated signaling networks between tumor cells and tumor microenvironment, 
which may explain the large difference between cluster 3 and 4.  
 
Figure 4.14. Cytokines and growth factors target a significant number of differentially expressed genes in cluster 
3 and cluster 4 samples. A. Number of differentially expressed genes targeted by cytokines and growth-factors. 
B. Number of activated cytokine or growth factor upstream regulators in cluster 3 and cluster 4 samples 
(activation z-score >3, p-value<0.001). C. Lists of overexpressed growth factors (blue) and cytokines (orange) in 
cluster 3 samples.  
 The major fractions of non-malignant cells in the tumor microenvironment are 
stromal and immune cells. We used a computational method ‘ESTIMATE’ to relatively 
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quantify the amount of stromal and immune cell infiltration in each NBL, based on 
ssGSEA score of 141 stromal signature genes and 141 immune signature genes 
(Yoshihara et al., 2013). Stromal signature scores showed that stromal cell infiltration is 
different among four clusters (Figure 4.15 A-B, ANOVA test, p<0.0001). Cluster 3 
samples had the highest stromal scores among all clusters. Consequently, infiltrating 
stromal cells create the unique inflammatory environment in NBLs, which could explain 
the inflammatory process characterized by overexpressed cytokines and growth factors in 
cluster 3 found by differential gene analysis. Moreover, immune signature scores show 
different levels of immune cell infiltration among four clusters (Figure 4.15 C-D, 
ANOVA test, p<0.0001). Both cluster 3 and cluster 4 samples showed high levels of 
immune cell infiltration, while cluster 1 NBLs had the lowest immune scores. As tumor 
stroma is associated with certain types of immune cells recruitment including NK cells, 
macrophages and dendritic cells (Fridman et al., 2012; Li et al., 2007), it is likely that 
high levels of stromal infiltration results in elevated immune infiltration in cluster 3. 
However, as stromal infiltration in cluster 4 is significantly lower compared to cluster 3, 
it is reasonable to assume that other mechanisms contribute to the elevated immune 
infiltration in cluster 4. Therefore, the evidence suggests that different types of immune 
cells contribute to elevated immune signature score in cluster 3 and 4 separately.   
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Figure 4.15. Computational analysis of infiltrating stromal cells and immune cells in NBLs. A.ssGSEA score 
based on 141 stromal signature genes for all samples (left panel), and stage 4 MYCN-NA samples (right panel). 
ANOVA test showed different stromal scores among four clusters (p<0.0001). B. ssGSEA scores based on 141 
immune signature genes for all samples (left panel), and stage 4 MYCN-NA samples (right panels). ANOVA test 
showed different immune scores among four clusters (p<0.0001). 
 
 
  
 
86 
Types of immune cell infiltrations in NBLs 
 As discussed in the last section, cluster 3 and cluster 4 have elevated, yet 
probably different types of immune cell infiltration. In the tumor microenvironment, 
different types of infiltrating immune cells affect tumor progression in different ways 
(Fridman et al., 2012). In particular, it is well established that tumor associated 
macrophages (TAM) favor tumor progression and metastasis, while cytotoxic T (Tc) cells 
attack tumor cells (Quail and Joyce, 2013).  Moreover, in a context- and tumor- 
dependent manner, regulatory T (Treg) cells promote tumor progression, while B cells 
promote Tc cell responses against cancer (Lindau et al., 2013; Nelson, 2010).  Here, I 
used immune cell marker mRNA expression to analyze immune cell types activated in 
NBLs.  
 Hierarchical clustering showed clear separation with immune cell markers in 
NBLs. Interestingly, tumor growth promoting markers (CD4, CSF1R, CD11B, CD14, 
CD163, CD206 and CD25) for TAM and Treg cells were clustered together, while tumor 
growth suppressive markers (CD3E, CD3D, CD3G, CD8A, CD8B, CD19 and CD20) for 
Tc and B cells were clustered together (Figure 4.16A). In general, cluster 3 samples had 
high expression of tumor-promoting TAM (CD68, CD14, CD11B, CSF1R, CD163 and 
CD206), and Treg cell markers (CD4 and CD25). On the contrary, cluster 4 samples had 
high expression of tumor-killing Tc cell markers (CD3D, CD3E, CD3G, CD8A, and 
CD8B) and B cell markers (CD19 and CD20). Therefore, types of infiltrating immune 
cells are essentially different between clusters 3 and 4 samples, with cluster 3 samples 
associated with tumor growth promoting immune signatures, and cluster 4 samples 
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associated with tumor growth suppressive immune signatures, which could contribute to 
worse overall survival of cluster 3 compared to that of cluster 4.   
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Figure 4.16. Types of infiltrating immune cells in NBLs. A. Hierarchical clustering of NBLs based on pro-tumor 
TAM and Treg cell markers, as well as anti-tumor Tc and B cell markers. One cluster of samples (mostly cluster 
3 tumors) were highlighted with elevated pro-tumor markers, while another cluster of samples (mostly cluster 4 
NBLs) were highlighted with elevated anti-tumor markers. B, mRNA expression of TAM makers in 4 NBL 
clusters, where cluster 3 samples had the highest expression. C. mRNA expression of Tc cell markers in 4 NBL 
clusters, where cluster 4 samples had the highest expression.  
 Since cluster 3 with a pro-tumor growth immune signature had worse survival 
outcomes compared to cluster 4 samples with a tumor-killing immune signature, I 
investigated whether expression of specific immune cell markers can serve as a survival 
outcome predictor in NBLs. Because high MYCN signature is a dominant predictor for 
the survival outcome of MYCN-NA samples, and the immune cell infiltration is low in 
high MYCN signature samples (as displayed in Figure 4.15AB, cluster 1), I tested 
whether immune cell type markers can distinguish the survival outcomes in MYCN-NA 
samples with a low MYCN signature (n=41). As expected, higher expression of CD206, 
a pro-tumor growth TAM marker, was associated with worse outcome (Figure 4.17A, 
log-ranked test, p=0.009). Combining with high MYCN signature samples, MYCN-NA 
samples were stratified into three groups, high MYCN signature, low MYCN but high 
TAM signature, low MYCN and low TAM signature, ranking from the worst to the best  
outcomes (Figure 4.17B, log-ranked test, p=0.002). Conversely, there was an association 
between high expression of CD8A, an anti-tumor Tc cell marker, to better survival 
outcomes for stage 4 MYCN-NA samples with low MYCN signature (Figure 4.17C-D, 
log-ranked test, p=0.14 and p=0.004).  
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Figure 4.17. Survival analysis based on pro-tumor or anti-tumor immune cell markers. A.  Kaplan-Meyer 
analysis showed that high expression of pro-tumor immune cell marker CD206 was associated with worse 
survival in MYCN-NA samples with a low MYCN signature (log-ranked test, p=0.009). B. Separated survival 
outcomes stratified by MYCN signature and CD206 expression in all MYCN-NA samples (log-ranked test, 
p=0.002). C. Kaplan-Meyer analysis showed that high expression of anti-tumor immune cell marker CD8A has a 
trend towards better survival outcomes in MYCN-NA samples with a low MYCN signature (log-ranked test, 
p=0.14). D. Separated survival outcomes stratified by MYCN signature and CD8A expression in all MYCN-NA 
samples (log-ranked test, p=0.004). 
Studies have shown that neoantigens, which are created by protein coding 
mutations with potential MHC binding peptides, induces Tc cell activity (Schumacher 
and Schreiber, 2015). As discussed earlier, cluster 4 samples have elevated Tc cell 
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activities compared to other clusters. As reported in recent studies, NBLs are predicted to 
occasionally or regularly form neoantigens depending on the number of somatic non-
silent SNVs, with the majority of samples occasionally forming neoantigen, and some 
samples with higher number of somatic non-silent SNVs regularly forming neoantigens 
(Alexandrov et al., 2013; Linnemann et al., 2015; Schumacher and Schreiber, 2015). 
Therefore I tested whether the number of expressed somatic SNVs were different among 
four clusters. Interestingly, cluster 4 samples harbor higher number of expressed SNVs 
compared to cluster 2 and 3 samples, which is consistent with higher Tc cell marker 
expression in cluster 4 samples (Figure 4.18A, p<0.05). Interestingly, samples with 
higher expressed somatic SNVs (n≥10) had moderately better survival outcomes 
compared to samples with low expressed somatic SNVs (n<10) in cluster 3 and 4 
samples (Figure 4.18B, p=0.24).  
 
Figure 4.18. Cluster 4 samples have higher numbers of expressed somatic SNVs. A. Cluster 4 samples have 
higher number of expressed SNVs compared to cluster 2 and cluster 3 samples (* p<0.05). Average number of 
expressed SNVs  are shown by lines. B. Kaplan-Meyer analysis showed that NBLs with higher number of 
expressed SNVs have moderately better survival outcomes (log-ranked test, p=0.24).  
  
 
92 
Discussion 
 Our integrated RNA and DNA sequencing studies identified genomic alteration 
events including ALK, ATRX, and MYCN somatic mutations, as well as FOXR1 and ALK 
fusions. However, the most significant finding in this study is the identification of the 
four expression clusters, which correlated with genomic alterations, clinical features, and 
tumor microenvironment.   
The most prevalent subtype in our cohort is stage 4 MYCN-NA subtype (97 out of 
150 NBLs), which is characterized by the heterogeneous nature of these tumors (Guo et 
al., 2011; Molenaar et al., 2012). In this study, we showed that many of them have an 
elevated downstream MYCN signature, probably caused by various genomic events, such 
as MYCN P44L mutation, NRAS G13R mutation, and FOXR1 fusion. Additionally, tumor 
microenvironment are vastly different among stage 4 MYCN-NA NBLs. Those in cluster 
3 had an inflammatory signature with elevated cytokine and growth factor expression, as 
well as a high stromal cell infiltration. Additionally, these tumors had a higher expression 
of tumor growth promoting immune markers. On the contrary, stage 4 MYCN-NA NBLs 
in cluster 4 had an elevated expression of tumor growth suppressor immune markers, 
which potentially contributed by neoantigens generated by expressed somatic mutations. 
Our study indicates that patients currently categorized in to stage 4 MYCN-NA subtype 
can be further stratified by MYCN activating signature and tumor microenvironment. 
Some patients may benefit from therapies targeting tumors with MYCN amplification, or 
immune-based therapies including check point inhibitors in the future trials. 
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To summarize, we have performed an integrative analysis of the neuroblastoma 
genome and transcriptome with unprecedented resolution. Our work identified new 
molecular subtypes of NBL with potential clinical implications. In order to provide 
further evidence of these molecular subgroups, independent cohorts with large number of 
NBLs should be evaluated.  
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CHAPTER FIVE: ONGOING PROJECTS AND COLLABORATIONS 
Long non-coding gene expression in NBLs 
Across the whole genome, there were 1103 lncRNAs had the median expression 
higher than 0.5 FPKM. Similarly, 14166 protein coding genes had a higher than 0.5 
FPKM median expression in 150 NBLs cohort. For expressed genes (defined by median 
expression higher than 0.5), protein coding genes had a significantly higher expression 
compared to lncRNAs (Figure 5.1A, p<0.0001). However, some lncRNAs were highly 
expressed in NBLs. In particular, 16 lncRNAs had a median expression higher than 50 
FPKM; 246 lncRNAs had a median expression in between 5 to 50 FPKM; and 825 
lncRNAs had a median expression in between 0.5 to 5 FPKM (Figure 5.1B).   
 
Figure 5.1 Overall lncRNA expression in NBLs. A. The expression of protein coding genes vs. lncRNA. Protein 
coding gene has a higher average FPKM value of 3.2, while lncRNA has an average FPKM of 1.6 (p<0.0001). B. 
The number of lncRNAs in each FPKM bin.  While the majority of lncRNAs were expressed lower than 5 
FPKM, some of them were still highly expressed.  
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Next I looked for differentially expressed lncRNAs between patients who 
survived from the disease to ones who did not. Twenty-four lncRNAs were differentially 
expressed, of which eighteen lncRNAs were significantly higher (FDR<0.05, fold change 
>2) in patients who died from the disease (Figure 5.2A). In particular, lncRNA PVT1 has 
higher expression in patients who died from the disease, and was generally highly 
expressed in NBLs. In addition, Kaplan-Meyer analysis showed that high level of PVT1 
was associated with worse prognosis in all samples, stage 4 samples, and stage 4 MYCN-
NA samples only (Figure 5.2B-D, p<0.01). This was further confirmed by two 
independent microarray studies in all stage NBLs, and stage 4 MYCN-NA NBLs (Figure 
5.2E-F, p<0.01). Interestingly, PVT1 is located adjacent to MYC locus, in the human 
chromosome 8q24 region. 8q24 region is frequently associated with various genomic 
aberrations including amplifications, and translocations (Enciso-Mora et al., 2010; Huppi 
et al., 2012; Northcott et al., 2012). Previously, protein-coding gene MYC is the focus of 
the study in this region. However several studies indicate that PVT1 not only is associated 
with patient survival, and contributed to tumor pathogenesis and drug sensitivity when 
over-expressed (Guan et al., 2007; You et al., 2011). Moreover, PVT1 was identified as a 
susceptibility locus in various cancer GWAS study (Cerhan et al., 2014; Enciso-Mora et 
al., 2010; Matullo et al., 2013; Meyer et al., 2011; Skibola et al., 2014; Wolpin et al., 
2014). More recently, Tseng et al. discovered that high expression of PVT1 is required to 
stabilize MYC protein in vivo and in vitro (Tseng et al., 2014). As described in chapter 
four, fifty-eight percent of MYCN-NA samples display high MYCN signature, many 
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through genomic aberrations. Our data leads us to hypothesize that lncRNA PVT1 to be 
an oncogenic driver by promoting MYC/MYCN signature in NBLs. 
 
  
 
97 
Figure 5.2 LncRNAs that differentially expressed in patients with different survival outcomes. A. Twenty-four 
lncRNAs were differentially expressed, of which eighteen lncRNAs were significantly higher (FDR<0.05, fold 
change >2) in patients who died from the disease. FPKM values were plotted for NBL patients with different 
survival outcomes. Kaplan-Meyer analysis showed that high level of PVT1 was associated with worse prognosis 
in B. all samples, C. stage 4 samples, and D. stage 4 MYCN-NA samples only (log-ranked test, p<0.01).Kaplan-
Meyer analysis showed that high level of PVT1 was associated with worse prognosis in two independent NBL 
cohorts; E. stage 1, 2, 3, 4 NBL cohort (n=56, log-ranked test, p=5.9E=10). F. stage 4 MYCN-NA NBL cohort 
(n=102 log-ranked test, p=0.006).  
Functional study of lncRNA PVT1 
Analysis showed that PVT1 is involved in gene fusions in two tumor samples 
(stage 4 MYCN-NA NB2021 and stage 4 MYCN-A NB2050),  and one NBL cell line 
(SHSY5Y). In tumor NB2021, intra-chromosomally PVT1 exon 1 was fused with MYC 
exon 2, inter-chromosomally the same breakpoint of PVT1 was fused with chr4 
GALNTL6 exon 6 (Figure 5.3A-B).  Interestingly, the expression of PVT1, MYC, and 
GALNTL6 is significantly higher in this sample compared to other samples (Figure 5.3C). 
Tumor NB2050 harbored a PVT1-ARID1B fusion, with the first 3 exons of PVT1 fused to 
chr6 ARID1B exon 2 (Figure 5.3A-B). The expression of PVT1 and ARID1B is not 
different from other samples (Figure 5.3D). It is not clear how did the PVT1-ARID1B 
fusions affect the protein coding gene ARID1B, which was reported to be a tumor 
suppressor with loss of function mutations somatically driving oncogenesis in several 
tumors including NBL (Pugh et al., 2012; Sausen et al., 2013; Stephens et al., 2012).  
Additionally, inter-chromosomal PVT1-EXOC4 was detected in MYCN-NA NBL cell line 
SHSY5Y. Exon 6 of PVT1 was fused to exon 8 of EXOC4 on chromosome 7. Similar to 
tumor sample NB2050, the expression of fusion partners did not show change compared 
to other samples (Figure 5.3A, E).  PVT1 fusions are reported in various tumor types 
including lymphoid malignancies (Rack et al., 1998), small-cell lung cancer (Pleasance et 
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al., 2010), medulloblastoma (Northcott et al., 2012), multiple myeloma (Nagoshi et al., 
2012),  and gastric cancer (Kim et al., 2014). It is first time that PVT1 fusions reported in 
NBL.  
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Figure 5.3 PVT1 fusion in NBL tumors and cell line. A. Fusion gene structures in two NBL tumors and cell line. 
B. Genomic locations of PVT1 and its fusion partners. C-E. Expression of PVT1 or its fusion partner genes. Log2 
(FPKM) values are plotted in blue for fusion-negative samples. Mean value is also plotted in black line. 
****p<0.0001. Log2 (FPKM) values are plotted in red for fusion-positive samples.  C. Expression of PVT1 or its 
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partner genes GALNTL6 or MYC in NB2021. D. Expression of PVT1 or ARID1B in NB2050. E. Expression of 
PVT1 or EXOC4 in the cell line SHSY5Y.  
 We examined the binding of MYCN to the genomic loci of PVT1 using ChIP-seq 
on a MYCN inducible cell line (MYCN-3) (Shohet et al., 2011). We found strong MYCN 
binding signals in the promoter and 5’ region of PVT1 (Figure 5.4A). This observation is 
in consistent with previous report that PVT1 is a downstream target of MYC family 
transcription factors (Carramusa et al., 2007). Additionally, expression of PVT1 is 
correlated with expression of MYCN in 150 NBL tumors (Figure 5.4B, cor=0.3, 
p=0.0002). As described in chapter four, MYC expression also contributed for MYCN 
signature in NBLs. Here PVT1 expression is even better correlated with the sum of MYC 
and MYCN expression (Figure 5.4C, cor=0.39, p=6.3E-7). Our data leads us to 
hypothesize that that PVT1 promotes MYCN signature by stabilizing MYC/MYCN 
protein in NBL in keeping with previous publications for MYC . PVT1-MYC/MYCN 
could form a positive feedback to by transcriptional activating of PVT1 gene with 
MYC/MYCN protein. These need further validation in future experiments.  
Taken together, lncRNA PVT1 is an attractive candidate to target MYCN 
signature in NBLs. Thus we are continuing to work with the Bagchi lab at University of 
Minnesoda on functional study of PVT1 in NBL in vitro and in vivo. The first phase 
includes to knock down PVT1 (using siRNA and Anti-Sense Oligo (ASO)) and monitor 
cell proliferation/death and cell cycle arrest, as well as to measure MYC and MYCN 
protein levels and phosphorylation upon PVT1 inhibitor treatment with a range of 
dosage.   If PVT1 inhibition causes any cell growth repression in the cell lines, the second 
  
 
101 
phase includes to test the inhibitor in previous established mouse xenograft models using 
neuroblastoma cell lines.  
 
 
Figure 5.4. MYCN regulates the expression of PVT1. A. ChIP-seq shows MYCN binds to the promoter and 5’ 
end regions (red tracks) of PVT1. B. Expression of PVT1 is correlated with expression of MYCN (cor=0.30, 
p=0.0002) and C. the sum of MYC and MYCN (cor=0.39, p=6.3E-7) 
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State of the project at the time of writing and future plans 
 Project one is finished. The paper for project one is accepted by the 
journal of Cancer Letter. Additionally, I am preparing the manuscript for 
project two. BIBLIOGRAPHY 
(2004). Finishing the euchromatic sequence of the human genome. Nature 431, 931-945. 
Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A., Behjati, S., Biankin, A. 
V., Bignell, G. R., Bolli, N., Borg, A., Borresen-Dale, A. L., et al. (2013). Signatures of 
mutational processes in human cancer. Nature 500, 415-421. 
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, 
A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009). Systematic RNA interference 
reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112. 
Bemmo, A., Dias, C., Rose, A. A., Russo, C., Siegel, P., and Majewski, J. (2010). Exon-
level transcriptome profiling in murine breast cancer reveals splicing changes specific to 
tumors with different metastatic abilities. PloS one 5, e11981. 
Benard, J., Raguenez, G., Kauffmann, A., Valent, A., Ripoche, H., Joulin, V., Job, B., 
Danglot, G., Cantais, S., Robert, T., et al. (2008). MYCN-non-amplified metastatic 
neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of 
stage 4S. Molecular oncology 2, 261-271. 
Bindea, G., Mlecnik, B., Hackl, H., Charoentong, P., Tosolini, M., Kirilovsky, A., 
Fridman, W. H., Pages, F., Trajanoski, Z., and Galon, J. (2009). ClueGO: a Cytoscape 
plug-in to decipher functionally grouped gene ontology and pathway annotation 
networks. Bioinformatics 25, 1091-1093. 
Brodeur, G. M., and Bagatell, R. (2014). Mechanisms of neuroblastoma regression. 
Nature reviews Clinical oncology 11, 704-713. 
Carramusa, L., Contino, F., Ferro, A., Minafra, L., Perconti, G., Giallongo, A., and Feo, 
S. (2007). The PVT-1 oncogene is a Myc protein target that is overexpressed in 
transformed cells. Journal of cellular physiology 213, 511-518. 
Cerhan, J. R., Berndt, S. I., Vijai, J., Ghesquieres, H., McKay, J., Wang, S. S., Wang, Z., 
Yeager, M., Conde, L., de Bakker, P. I., et al. (2014). Genome-wide association study 
identifies multiple susceptibility loci for diffuse large B cell lymphoma. Nature genetics 
46, 1233-1238. 
  
 
103 
Chen, M., David, C. J., and Manley, J. L. (2012). Concentration-dependent control of 
pyruvate kinase M mutually exclusive splicing by hnRNP proteins. Nature structural & 
molecular biology 19, 346-354. 
Chen, M., Zhang, J., and Manley, J. L. (2010). Turning on a fuel switch of cancer: 
hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA. Cancer research 
70, 8977-8980. 
Chettouh, H., Fartoux, L., Aoudjehane, L., Wendum, D., Claperon, A., Chretien, Y., Rey, 
C., Scatton, O., Soubrane, O., Conti, F., et al. (2013). Mitogenic insulin receptor-A is 
overexpressed in human hepatocellular carcinoma due to EGFR-mediated dysregulation 
of RNA splicing factors. Cancer Res 73, 3974-3986. 
Cheung, H. C., Baggerly, K. A., Tsavachidis, S., Bachinski, L. L., Neubauer, V. L., 
Nixon, T. J., Aldape, K. D., Cote, G. J., and Krahe, R. (2008). Global analysis of aberrant 
pre-mRNA splicing in glioblastoma using exon expression arrays. BMC genomics 9, 216. 
Cheung, N. K., Zhang, J., Lu, C., Parker, M., Bahrami, A., Tickoo, S. K., Heguy, A., 
Pappo, A. S., Federico, S., Dalton, J., et al. (2012). Association of age at diagnosis and 
genetic mutations in patients with neuroblastoma. Jama 307, 1062-1071. 
Chinnam, M., and Goodrich, D. W. (2011). RB1, development, and cancer. Current 
topics in developmental biology 94, 129-169. 
Christofk, H. R., Vander Heiden, M. G., Harris, M. H., Ramanathan, A., Gerszten, R. E., 
Wei, R., Fleming, M. D., Schreiber, S. L., and Cantley, L. C. (2008). The M2 splice 
isoform of pyruvate kinase is important for cancer metabolism and tumour growth. 
Nature 452, 230-233. 
Cline, M. S., Smoot, M., Cerami, E., Kuchinsky, A., Landys, N., Workman, C., 
Christmas, R., Avila-Campilo, I., Creech, M., Gross, B., et al. (2007). Integration of 
biological networks and gene expression data using Cytoscape. Nature protocols 2, 2366-
2382. 
Clower, C. V., Chatterjee, D., Wang, Z., Cantley, L. C., Vander Heiden, M. G., and 
Krainer, A. R. (2010). The alternative splicing repressors hnRNP A1/A2 and PTB 
influence pyruvate kinase isoform expression and cell metabolism. Proceedings of the 
National Academy of Sciences of the United States of America 107, 1894-1899. 
Cohn, S. L., Pearson, A. D., London, W. B., Monclair, T., Ambros, P. F., Brodeur, G. M., 
Faldum, A., Hero, B., Iehara, T., Machin, D., et al. (2009). The International 
Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. 
Journal of clinical oncology : official journal of the American Society of Clinical 
Oncology 27, 289-297. 
  
 
104 
consortium, E. p. (2012). An integrated encyclopedia of DNA elements in the human 
genome. Nature 489, 57-74. 
consortium, h. g. p. (2001). Initial sequencing and analysis of the human genome. Nature 
409, 860-921. 
Cortes-Cros, M., Hemmerlin, C., Ferretti, S., Zhang, J., Gounarides, J. S., Yin, H., 
Muller, A., Haberkorn, A., Chene, P., Sellers, W. R., and Hofmann, F. (2013). M2 
isoform of pyruvate kinase is dispensable for tumor maintenance and growth. 
Proceedings of the National Academy of Sciences of the United States of America 110, 
489-494. 
David, C. J., Chen, M., Assanah, M., Canoll, P., and Manley, J. L. (2010). HnRNP 
proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. 
Nature 463, 364-368. 
Deyell, R. J., and Attiyeh, E. F. (2011). Advances in the understanding of constitutional 
and somatic genomic alterations in neuroblastoma. Cancer genetics 204, 113-121. 
Douglass, E. C., Valentine, M., Etcubanas, E., Parham, D., Webber, B. L., Houghton, P. 
J., Houghton, J. A., and Green, A. A. (1987). A specific chromosomal abnormality in 
rhabdomyosarcoma. Cytogenetics and cell genetics 45, 148-155. 
Dutertre, M., Lacroix-Triki, M., Driouch, K., de la Grange, P., Gratadou, L., Beck, S., 
Millevoi, S., Tazi, J., Lidereau, R., Vagner, S., and Auboeuf, D. (2010). Exon-Based 
Clustering of Murine Breast Tumor Transcriptomes Reveals Alternative Exons Whose 
Expression Is Associated with Metastasis. Cancer Res 70, 896-905. 
Enciso-Mora, V., Broderick, P., Ma, Y., Jarrett, R. F., Hjalgrim, H., Hemminki, K., van 
den Berg, A., Olver, B., Lloyd, A., Dobbins, S. E., et al. (2010). A genome-wide 
association study of Hodgkin's lymphoma identifies new susceptibility loci at 2p16.1 
(REL), 8q24.21 and 10p14 (GATA3). Nature genetics 42, 1126-1130. 
Engelmann, D., and Putzer, B. M. (2012). The dark side of E2F1: in transit beyond 
apoptosis. Cancer research 72, 571-575. 
Ferrarese, R., Harsh, G. R. t., Yadav, A. K., Bug, E., Maticzka, D., Reichardt, W., 
Dombrowski, S. M., Miller, T. E., Masilamani, A. P., Dai, F., et al. (2014). Lineage-
specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. 
The Journal of clinical investigation 124, 2861-2876. 
Forbes, S. A., Beare, D., Gunasekaran, P., Leung, K., Bindal, N., Boutselakis, H., Ding, 
M., Bamford, S., Cole, C., Ward, S., et al. (2015). COSMIC: exploring the world's 
knowledge of somatic mutations in human cancer. Nucleic acids research 43, D805-811. 
  
 
105 
Fredlund, E., Ringner, M., Maris, J. M., and Pahlman, S. (2008). High Myc pathway 
activity and low stage of neuronal differentiation associate with poor outcome in 
neuroblastoma. Proceedings of the National Academy of Sciences of the United States of 
America 105, 14094-14099. 
Fridman, W. H., Pages, F., Sautes-Fridman, C., and Galon, J. (2012). The immune 
contexture in human tumours: impact on clinical outcome. Nature reviews Cancer 12, 
298-306. 
Gardina, P. J., Clark, T. A., Shimada, B., Staples, M. K., Yang, Q., Veitch, J., 
Schweitzer, A., Awad, T., Sugnet, C., Dee, S., et al. (2006). Alternative splicing and 
differential gene expression in colon cancer detected by a whole genome exon array. 
BMC genomics 7, 325. 
George, R. E., Sanda, T., Hanna, M., Frohling, S., Luther, W., 2nd, Zhang, J., Ahn, Y., 
Zhou, W., London, W. B., McGrady, P., et al. (2008). Activating mutations in ALK 
provide a therapeutic target in neuroblastoma. Nature 455, 975-978. 
Germann, S., Gratadou, L., Dutertre, M., and Auboeuf, D. (2012). Splicing programs and 
cancer. Journal of nucleic acids 2012, 269570. 
Gogolin, S., Batra, R., Harder, N., Ehemann, V., Paffhausen, T., Diessl, N., Sagulenko, 
V., Benner, A., Gade, S., Nolte, I., et al. (2013). MYCN-mediated overexpression of 
mitotic spindle regulatory genes and loss of p53-p21 function jointly support the survival 
of tetraploid neuroblastoma cells. Cancer letters 331, 35-45. 
Goldberg, M. S., and Sharp, P. A. (2012). Pyruvate kinase M2-specific siRNA induces 
apoptosis and tumor regression. The Journal of experimental medicine 209, 217-224. 
Guan, Y., Kuo, W. L., Stilwell, J. L., Takano, H., Lapuk, A. V., Fridlyand, J., Mao, J. H., 
Yu, M., Miller, M. A., Santos, J. L., et al. (2007). Amplification of PVT1 contributes to 
the pathophysiology of ovarian and breast cancer. Clinical cancer research : an official 
journal of the American Association for Cancer Research 13, 5745-5755. 
Guo, C., White, P. S., Weiss, M. J., Hogarty, M. D., Thompson, P. M., Stram, D. O., 
Gerbing, R., Matthay, K. K., Seeger, R. C., Brodeur, G. M., and Maris, J. M. (1999). 
Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene 
18, 4948-4957. 
Guo, X., Chen, Q. R., Song, Y. K., Wei, J. S., and Khan, J. (2011). Exon array analysis 
reveals neuroblastoma tumors have distinct alternative splicing patterns according to 
stage and MYCN amplification status. BMC medical genomics 4, 35. 
  
 
106 
Gutschner, T., and Diederichs, S. (2012a). The hallmarks of cancer: a long non-coding 
RNA point of view. RNA biology 9, 703-719. 
Gutschner, T., and Diederichs, S. (2012b). The Hallmarks of Cancer: A long non-coding 
RNA point of view. RNA biology 9. 
Harris, A. L. (2002). Hypoxia--a key regulatory factor in tumour growth. Nature reviews 
Cancer 2, 38-47. 
Huang, Y., Lin, L., Yu, X., Wen, G., Pu, X., Zhao, H., Fang, C., Zhu, J., Ye, S., Zhang, 
L., and Xiao, Q. (2013). Functional involvements of heterogeneous nuclear 
ribonucleoprotein A1 in smooth muscle differentiation from stem cells in vitro and in 
vivo. Stem Cells 31, 906-917. 
Huppi, K., Pitt, J. J., Wahlberg, B. M., and Caplen, N. J. (2012). The 8q24 gene desert: an 
oasis of non-coding transcriptional activity. Frontiers in genetics 3, 69. 
Israelsen, W. J., Dayton, T. L., Davidson, S. M., Fiske, B. P., Hosios, A. M., Bellinger, 
G., Li, J., Yu, Y., Sasaki, M., Horner, J. W., et al. (2013). PKM2 isoform-specific 
deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell 155, 
397-409. 
Janoueix-Lerosey, I., Lequin, D., Brugieres, L., Ribeiro, A., de Pontual, L., Combaret, V., 
Raynal, V., Puisieux, A., Schleiermacher, G., Pierron, G., et al. (2008). Somatic and 
germline activating mutations of the ALK kinase receptor in neuroblastoma. Nature 455, 
967-970. 
Jun S. Wei, P. J., Li Chen, Young K. Song, Catherine Tolman, Samuel Li, Laura Hurd, 
Rajesh Patidar, Xinyu Wen, Thomas C. Badgett, Adam T.C. Cheuk, Jean-Claude 
Marshall, Patricia S. Steeg, José P. Vaqué Díez , J. Silvio Gutkind4 Javed Khan (2013). 
Massively Parallel Sequencing Reveals an Accumulation of De Novo Mutations and an 
Activating Mutation of LPAR1 in a Patient with Metastatic Neuroblastoma. Submitted. 
Khan, J., Wei, J. S., Ringner, M., Saal, L. H., Ladanyi, M., Westermann, F., Berthold, F., 
Schwab, M., Antonescu, C. R., Peterson, C., and Meltzer, P. S. (2001). Classification and 
diagnostic prediction of cancers using gene expression profiling and artificial neural 
networks. Nature medicine 7, 673-679. 
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., and Salzberg, S. L. (2013a). 
TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions 
and gene fusions. Genome biology 14, R36. 
Kim, H. J., Kim, N. C., Wang, Y. D., Scarborough, E. A., Moore, J., Diaz, Z., MacLea, 
K. S., Freibaum, B., Li, S., Molliex, A., et al. (2013b). Mutations in prion-like domains in 
  
 
107 
hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature 495, 467-
473. 
Kim, H. P., Cho, G. A., Han, S. W., Shin, J. Y., Jeong, E. G., Song, S. H., Lee, W. C., 
Lee, K. H., Bang, D., Seo, J. S., et al. (2014). Novel fusion transcripts in human gastric 
cancer revealed by transcriptome analysis. Oncogene 33, 5434-5441. 
Langer, W., Sohler, F., Leder, G., Beckmann, G., Seidel, H., Grone, J., Hummel, M., and 
Sommer, A. (2010). Exon array analysis using re-defined probe sets results in reliable 
identification of alternatively spliced genes in non-small cell lung cancer. BMC genomics 
11, 676. 
Li, H., Fan, X., and Houghton, J. (2007). Tumor microenvironment: the role of the tumor 
stroma in cancer. Journal of cellular biochemistry 101, 805-815. 
Lindau, D., Gielen, P., Kroesen, M., Wesseling, P., and Adema, G. J. (2013). The 
immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells 
and natural killer T cells. Immunology 138, 105-115. 
Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M., Schotte, R., Calis, J. J., 
Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2015). High-throughput 
epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human 
melanoma. Nature medicine 21, 81-85. 
Liu, L., Li, Y., Li, S., Hu, N., He, Y., Pong, R., Lin, D., Lu, L., and Law, M. (2012). 
Comparison of next-generation sequencing systems. Journal of biomedicine & 
biotechnology 2012, 251364. 
London, W. B., Castleberry, R. P., Matthay, K. K., Look, A. T., Seeger, R. C., Shimada, 
H., Thorner, P., Brodeur, G., Maris, J. M., Reynolds, C. P., and Cohn, S. L. (2005). 
Evidence for an age cutoff greater than 365 days for neuroblastoma risk group 
stratification in the Children's Oncology Group. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 23, 6459-6465. 
Maher, C. A., Kumar-Sinha, C., Cao, X., Kalyana-Sundaram, S., Han, B., Jing, X., Sam, 
L., Barrette, T., Palanisamy, N., and Chinnaiyan, A. M. (2009a). Transcriptome 
sequencing to detect gene fusions in cancer. Nature 458, 97-101. 
Maher, C. A., Palanisamy, N., Brenner, J. C., Cao, X., Kalyana-Sundaram, S., Luo, S., 
Khrebtukova, I., Barrette, T. R., Grasso, C., Yu, J., et al. (2009b). Chimeric transcript 
discovery by paired-end transcriptome sequencing. Proceedings of the National Academy 
of Sciences of the United States of America 106, 12353-12358. 
  
 
108 
Maris, J. M. (2010). Recent advances in neuroblastoma. The New England journal of 
medicine 362, 2202-2211. 
Matullo, G., Guarrera, S., Betti, M., Fiorito, G., Ferrante, D., Voglino, F., Cadby, G., Di 
Gaetano, C., Rosa, F., Russo, A., et al. (2013). Genetic variants associated with increased 
risk of malignant pleural mesothelioma: a genome-wide association study. PloS one 8, 
e61253. 
Mazurek, S., Boschek, C. B., Hugo, F., and Eigenbrodt, E. (2005). Pyruvate kinase type 
M2 and its role in tumor growth and spreading. Semin Cancer Biol 15, 300-308. 
McPherson, A., Hormozdiari, F., Zayed, A., Giuliany, R., Ha, G., Sun, M. G., Griffith, 
M., Heravi Moussavi, A., Senz, J., Melnyk, N., et al. (2011). deFuse: an algorithm for 
gene fusion discovery in tumor RNA-Seq data. PLoS computational biology 7, e1001138. 
Meyer, K. B., Maia, A. T., O'Reilly, M., Ghoussaini, M., Prathalingam, R., Porter-Gill, 
P., Ambs, S., Prokunina-Olsson, L., Carroll, J., and Ponder, B. A. (2011). A functional 
variant at a prostate cancer predisposition locus at 8q24 is associated with PVT1 
expression. PLoS genetics 7, e1002165. 
Misquitta-Ali, C. M., Cheng, E., O'Hanlon, D., Liu, N., McGlade, C. J., Tsao, M. S., and 
Blencowe, B. J. (2011). Global profiling and molecular characterization of alternative 
splicing events misregulated in lung cancer. Molecular and cellular biology 31, 138-150. 
Molenaar, J. J., Koster, J., Zwijnenburg, D. A., van Sluis, P., Valentijn, L. J., van der 
Ploeg, I., Hamdi, M., van Nes, J., Westerman, B. A., van Arkel, J., et al. (2012). 
Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis 
genes. Nature. 
Monti, S., Tamayo, P., Mesirov, J., and Golub, T. (2003). Consensus clustering: A 
resampling-based method for class discovery and visualization of gene expression 
microarray data. Mach Learn 52, 91-118. 
Mosse, Y. P., Laudenslager, M., Khazi, D., Carlisle, A. J., Winter, C. L., Rappaport, E., 
and Maris, J. M. (2004). Germline PHOX2B mutation in hereditary neuroblastoma. 
American journal of human genetics 75, 727-730. 
Nadiminty, N., Tummala, R., Liu, C., Lou, W., Evans, C. P., and Gao, A. C. (2015). NF-
kappaB2/p52:c-Myc:hnRNPA1 pathway regulates expression of androgen receptor splice 
variants and enzalutamide sensitivity in prostate cancer. Mol Cancer Ther. 
Nagoshi, H., Taki, T., Hanamura, I., Nitta, M., Otsuki, T., Nishida, K., Okuda, K., 
Sakamoto, N., Kobayashi, S., Yamamoto-Sugitani, M., et al. (2012). Frequent PVT1 
  
 
109 
rearrangement and novel chimeric genes PVT1-NBEA and PVT1-WWOX occur in 
multiple myeloma with 8q24 abnormality. Cancer research 72, 4954-4962. 
Nelson, B. H. (2010). CD20+ B cells: the other tumor-infiltrating lymphocytes. J 
Immunol 185, 4977-4982. 
Northcott, P. A., Shih, D. J., Peacock, J., Garzia, L., Morrissy, A. S., Zichner, T., Stutz, 
A. M., Korshunov, A., Reimand, J., Schumacher, S. E., et al. (2012). Subgroup-specific 
structural variation across 1,000 medulloblastoma genomes. Nature 488, 49-56. 
Nowell, P. C. (1962). The minute chromosome (Phl) in chronic granulocytic leukemia. 
Blut 8, 65-66. 
Omura-Minamisawa, M., Diccianni, M. B., Chang, R. C., Batova, A., Bridgeman, L. J., 
Schiff, J., Cohn, S. L., London, W. B., and Yu, A. L. (2001). p16/p14(ARF) cell cycle 
regulatory pathways in primary neuroblastoma: p16 expression is associated with 
advanced stage disease. Clinical cancer research : an official journal of the American 
Association for Cancer Research 7, 3481-3490. 
Ozsolak, F., Platt, A. R., Jones, D. R., Reifenberger, J. G., Sass, L. E., McInerney, P., 
Thompson, J. F., Bowers, J., Jarosz, M., and Milos, P. M. (2009). Direct RNA 
sequencing. Nature 461, 814-818. 
Pan, Q., Shai, O., Lee, L. J., Frey, B. J., and Blencowe, B. J. (2008). Deep surveying of 
alternative splicing complexity in the human transcriptome by high-throughput 
sequencing. Nature genetics 40, 1413-1415. 
Parnell, K. M., Foulks, J. M., Nix, R. N., Clifford, A., Bullough, J., Luo, B., Senina, A., 
Vollmer, D., Liu, J., McCarthy, V., et al. (2013). Pharmacologic activation of PKM2 
slows lung tumor xenograft growth. Mol Cancer Ther 12, 1453-1460. 
Philip A. Pizzo, D. G. P. (2011). Principles and practice of pediatric oncology). 
Piva, F., Giulietti, M., Burini, A. B., and Principato, G. (2012). SpliceAid 2: a database of 
human splicing factors expression data and RNA target motifs. Human mutation 33, 81-
85. 
Pizzo, P. A., and Poplack, D. G. (2011). Principles and practice of pediatric oncology, 6th 
edn (Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins Health). 
Pleasance, E. D., Stephens, P. J., O'Meara, S., McBride, D. J., Meynert, A., Jones, D., 
Lin, M. L., Beare, D., Lau, K. W., Greenman, C., et al. (2010). A small-cell lung cancer 
genome with complex signatures of tobacco exposure. Nature 463, 184-190. 
  
 
110 
Prensner, J. R., Iyer, M. K., Balbin, O. A., Dhanasekaran, S. M., Cao, Q., Brenner, J. C., 
Laxman, B., Asangani, I. A., Grasso, C. S., Kominsky, H. D., et al. (2011). 
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an 
unannotated lincRNA implicated in disease progression. Nature biotechnology 29, 742-
749. 
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, 
S. L., Cibulskis, K., Hanna, M., Kiezun, A., et al. (2013a). The genetic landscape of high-
risk neuroblastoma. Nat Genet 45, 279-284. 
Pugh, T. J., Morozova, O., Attiyeh, E. F., Asgharzadeh, S., Wei, J. S., Auclair, D., Carter, 
S. L., Cibulskis, K., Hanna, M., Kiezun, A., et al. (2013b). The genetic landscape of 
high-risk neuroblastoma. Nature genetics 45, 279-284. 
Pugh, T. J., Weeraratne, S. D., Archer, T. C., Pomeranz Krummel, D. A., Auclair, D., 
Bochicchio, J., Carneiro, M. O., Carter, S. L., Cibulskis, K., Erlich, R. L., et al. (2012). 
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. 
Nature 488, 106-110. 
Quail, D. F., and Joyce, J. A. (2013). Microenvironmental regulation of tumor 
progression and metastasis. Nature medicine 19, 1423-1437. 
Quail, M. A., Smith, M., Coupland, P., Otto, T. D., Harris, S. R., Connor, T. R., Bertoni, 
A., Swerdlow, H. P., and Gu, Y. (2012). A tale of three next generation sequencing 
platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina MiSeq 
sequencers. BMC genomics 13, 341. 
Rack, K. A., Delabesse, E., Radford-Weiss, I., Bourquelot, P., Le Guyader, G., 
Vekemans, M., and Macintyre, E. A. (1998). Simultaneous detection of MYC, BVR1, 
and PVT1 translocations in lymphoid malignancies by fluorescence in situ hybridization. 
Genes Chromosomes Cancer 23, 220-226. 
Ramos, A. D., Andersen, R. E., Liu, S. J., Nowakowski, T. J., Hong, S. J., Gertz, C. C., 
Salinas, R. D., Zarabi, H., Kriegstein, A. R., and Lim, D. A. (2015). The long noncoding 
RNA Pnky regulates neuronal differentiation of embryonic and postnatal neural stem 
cells. Cell stem cell 16, 439-447. 
Rickman, D. S., Pflueger, D., Moss, B., VanDoren, V. E., Chen, C. X., de la Taille, A., 
Kuefer, R., Tewari, A. K., Setlur, S. R., Demichelis, F., and Rubin, M. A. (2009). 
SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion 
transcript in prostate cancer. Cancer research 69, 2734-2738. 
Roberts, K. G., Morin, R. D., Zhang, J., Hirst, M., Zhao, Y., Su, X., Chen, S. C., Payne-
Turner, D., Churchman, M. L., Harvey, R. C., et al. (2012). Genetic alterations activating 
  
 
111 
kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer 
cell 22, 153-166. 
Rodrigo-Domingo, M., Waagepetersen, R., Bodker, J. S., Falgreen, S., Kjeldsen, M. K., 
Johnsen, H. E., Dybkaer, K., and Bogsted, M. (2013). Reproducible probe-level analysis 
of the Affymetrix Exon 1.0 ST array with R/Bioconductor. Briefings in bioinformatics. 
Santo, E. E., Ebus, M. E., Koster, J., Schulte, J. H., Lakeman, A., van Sluis, P., 
Vermeulen, J., Gisselsson, D., Ora, I., Lindner, S., et al. (2012). Oncogenic activation of 
FOXR1 by 11q23 intrachromosomal deletion-fusions in neuroblastoma. Oncogene 31, 
1571-1581. 
Sausen, M., Leary, R. J., Jones, S., Wu, J., Reynolds, C. P., Liu, X., Blackford, A., 
Parmigiani, G., Diaz, L. A., Jr., Papadopoulos, N., et al. (2013). Integrated genomic 
analyses identify ARID1A and ARID1B alterations in the childhood cancer 
neuroblastoma. Nature genetics 45, 12-17. 
Schadt, E. E., Turner, S., and Kasarskis, A. (2010). A window into third-generation 
sequencing. Human molecular genetics 19, R227-240. 
Schaefer, C. F., Anthony, K., Krupa, S., Buchoff, J., Day, M., Hannay, T., and Buetow, 
K. H. (2009). PID: the Pathway Interaction Database. Nucleic acids research 37, D674-
679. 
Schneeberger, V. E., Luetteke, N., Ren, Y., Berns, H., Chen, L., Foroutan, P., Martinez, 
G. V., Haura, E. B., Chen, J., Coppola, D., and Wu, J. (2014). SHP2E76K mutant 
promotes lung tumorigenesis in transgenic mice. Carcinogenesis 35, 1717-1725. 
Schumacher, T. N., and Schreiber, R. D. (2015). Neoantigens in cancer immunotherapy. 
Science 348, 69-74. 
Shapiro, I. M., Cheng, A. W., Flytzanis, N. C., Balsamo, M., Condeelis, J. S., Oktay, M. 
H., Burge, C. B., and Gertler, F. B. (2011). An EMT-driven alternative splicing program 
occurs in human breast cancer and modulates cellular phenotype. PLoS genetics 7, 
e1002218. 
Shen, S., Park, J. W., Huang, J., Dittmar, K. A., Lu, Z. X., Zhou, Q., Carstens, R. P., and 
Xing, Y. (2012). MATS: a Bayesian framework for flexible detection of differential 
alternative splicing from RNA-Seq data. Nucleic Acids Res 40, e61. 
Shohet, J. M., Ghosh, R., Coarfa, C., Ludwig, A., Benham, A. L., Chen, Z., Patterson, D. 
M., Barbieri, E., Mestdagh, P., Sikorski, D. N., et al. (2011). A genome-wide search for 
promoters that respond to increased MYCN reveals both new oncogenic and tumor 
  
 
112 
suppressor microRNAs associated with aggressive neuroblastoma. Cancer research 71, 
3841-3851. 
Skibola, C. F., Berndt, S. I., Vijai, J., Conde, L., Wang, Z., Yeager, M., de Bakker, P. I., 
Birmann, B. M., Vajdic, C. M., Foo, J. N., et al. (2014). Genome-wide association study 
identifies five susceptibility loci for follicular lymphoma outside the HLA region. 
American journal of human genetics 95, 462-471. 
Slack, A., Chen, Z., Tonelli, R., Pule, M., Hunt, L., Pession, A., and Shohet, J. M. (2005). 
The p53 regulatory gene MDM2 is a direct transcriptional target of MYCN in 
neuroblastoma. Proceedings of the National Academy of Sciences of the United States of 
America 102, 731-736. 
Spizzo, R., Almeida, M. I., Colombatti, A., and Calin, G. A. (2012a). Long non-coding 
RNAs and cancer: a new frontier of translational research? Oncogene 31, 4577-4587. 
Spizzo, R., Almeida, M. I., Colombatti, A., and Calin, G. A. (2012b). Long non-coding 
RNAs and cancer: a new frontier of translational research? Oncogene. 
Stauffer, J. K., Orentas, R. J., Lincoln, E., Khan, T., Salcedo, R., Hixon, J. A., Back, T. 
C., Wei, J. S., Patidar, R., Song, Y., et al. (2012). High-throughput molecular and 
histopathologic profiling of tumor tissue in a novel transplantable model of murine 
neuroblastoma: new tools for pediatric drug discovery. Cancer investigation 30, 343-363. 
Steidl, C., Shah, S. P., Woolcock, B. W., Rui, L., Kawahara, M., Farinha, P., Johnson, N. 
A., Zhao, Y., Telenius, A., Neriah, S. B., et al. (2011). MHC class II transactivator 
CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 471, 377-381. 
Stephens, P. J., Tarpey, P. S., Davies, H., Van Loo, P., Greenman, C., Wedge, D. C., Nik-
Zainal, S., Martin, S., Varela, I., Bignell, G. R., et al. (2012). The landscape of cancer 
genes and mutational processes in breast cancer. Nature 486, 400-404. 
Storlazzi, C. T., Lonoce, A., Guastadisegni, M. C., Trombetta, D., D'Addabbo, P., 
Daniele, G., L'Abbate, A., Macchia, G., Surace, C., Kok, K., et al. (2010). Gene 
amplification as double minutes or homogeneously staining regions in solid tumors: 
origin and structure. Genome research 20, 1198-1206. 
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. 
A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., and Mesirov, J. P. (2005). 
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide 
expression profiles. Proceedings of the National Academy of Sciences of the United 
States of America 102, 15545-15550. 
  
 
113 
Sveen, A., Agesen, T. H., Nesbakken, A., Rognum, T. O., Lothe, R. A., and Skotheim, R. 
I. (2011). Transcriptome instability in colorectal cancer identified by exon microarray 
analyses: Associations with splicing factor expression levels and patient survival. 
Genome medicine 3, 32. 
Thomas-Chollier, M., Sand, O., Turatsinze, J. V., Janky, R., Defrance, M., Vervisch, E., 
Brohee, S., and van Helden, J. (2008). RSAT: regulatory sequence analysis tools. Nucleic 
acids research 36, W119-127. 
Trapnell, C., Roberts, A., Goff, L., Pertea, G., Kim, D., Kelley, D. R., Pimentel, H., 
Salzberg, S. L., Rinn, J. L., and Pachter, L. (2012). Differential gene and transcript 
expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nature 
protocols 7, 562-578. 
Trapnell, C., Williams, B. A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M. J., 
Salzberg, S. L., Wold, B. J., and Pachter, L. (2010). Transcript assembly and 
quantification by RNA-Seq reveals unannotated transcripts and isoform switching during 
cell differentiation. Nature biotechnology 28, 511-515. 
Trochet, D., Bourdeaut, F., Janoueix-Lerosey, I., Deville, A., de Pontual, L., 
Schleiermacher, G., Coze, C., Philip, N., Frebourg, T., Munnich, A., et al. (2004). 
Germline mutations of the paired-like homeobox 2B (PHOX2B) gene in neuroblastoma. 
American journal of human genetics 74, 761-764. 
Tseng, Y. Y., Moriarity, B. S., Gong, W., Akiyama, R., Tiwari, A., Kawakami, H., 
Ronning, P., Reuland, B., Guenther, K., Beadnell, T. C., et al. (2014). PVT1 dependence 
in cancer with MYC copy-number increase. Nature 512, 82-86. 
Valentijn, L. J., Koster, J., Haneveld, F., Aissa, R. A., van Sluis, P., Broekmans, M. E., 
Molenaar, J. J., van Nes, J., and Versteeg, R. (2012). Functional MYCN signature 
predicts outcome of neuroblastoma irrespective of MYCN amplification. Proceedings of 
the National Academy of Sciences of the United States of America 109, 19190-19195. 
van't Veer, L. J., and Bernards, R. (2008). Enabling personalized cancer medicine 
through analysis of gene-expression patterns. Nature 452, 564-570. 
van Helden, J., Andre, B., and Collado-Vides, J. (1998). Extracting regulatory sites from 
the upstream region of yeast genes by computational analysis of oligonucleotide 
frequencies. Journal of molecular biology 281, 827-842. 
Venables, J. P., Klinck, R., Koh, C., Gervais-Bird, J., Bramard, A., Inkel, L., Durand, M., 
Couture, S., Froehlich, U., Lapointe, E., et al. (2009). Cancer-associated regulation of 
alternative splicing. Nature structural & molecular biology 16, 670-676. 
  
 
114 
Verhaak, R. G., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, 
C. R., Ding, L., Golub, T., Mesirov, J. P., et al. (2010). Integrated genomic analysis 
identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in 
PDGFRA, IDH1, EGFR, and NF1. Cancer cell 17, 98-110. 
Warner, S. L., Carpenter, K. J., and Bearss, D. J. (2014). Activators of PKM2 in cancer 
metabolism. Future medicinal chemistry 6, 1167-1178. 
Wei, J. S., Johansson, P., Chen, L., Song, Y. K., Tolman, C., Li, S., Hurd, L., Patidar, R., 
Wen, X., Badgett, T. C., et al. (2013). Massively parallel sequencing reveals an 
accumulation of de novo mutations and an activating mutation of LPAR1 in a patient 
with metastatic neuroblastoma. PloS one 8, e77731. 
Wei, J. S., and Khan, J. (2002). Purification of total RNA from mammalian cells and 
tissues. In DNA microarrays: a molecular cloning manual, D. Bowtell, and J. Sambrook, 
eds. (Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press), pp. 110-
119. 
Wei, J. S., Song, Y. K., Durinck, S., Chen, Q. R., Cheuk, A. T., Tsang, P., Zhang, Q., 
Thiele, C. J., Slack, A., Shohet, J., and Khan, J. (2008). The MYCN oncogene is a direct 
target of miR-34a. Oncogene 27, 5204-5213. 
Wen, J., Toomer, K. H., Chen, Z., and Cai, X. (2015). Genome-wide analysis of 
alternative transcripts in human breast cancer. Breast cancer research and treatment 151, 
295-307. 
Westermark, U. K., Wilhelm, M., Frenzel, A., and Henriksson, M. A. (2011). The 
MYCN oncogene and differentiation in neuroblastoma. Seminars in cancer biology 21, 
256-266. 
Whitwam, T., Vanbrocklin, M. W., Russo, M. E., Haak, P. T., Bilgili, D., Resau, J. H., 
Koo, H. M., and Holmen, S. L. (2007). Differential oncogenic potential of activated RAS 
isoforms in melanocytes. Oncogene 26, 4563-4570. 
Wierstra, I., and Alves, J. (2007). FOXM1, a typical proliferation-associated transcription 
factor. Biological chemistry 388, 1257-1274. 
Wilkerson, M. D., and Hayes, D. N. (2010). ConsensusClusterPlus: a class discovery tool 
with confidence assessments and item tracking. Bioinformatics 26, 1572-1573. 
Williams, R. D., Chagtai, T., Alcaide-German, M., Apps, J., Wegert, J., Popov, S., 
Vujanic, G., van Tinteren, H., van den Heuvel-Eibrink, M. M., Kool, M., et al. (2015). 
Multiple mechanisms of MYCN dysregulation in Wilms tumour. Oncotarget 6, 7232-
7243. 
  
 
115 
Wolpin, B. M., Rizzato, C., Kraft, P., Kooperberg, C., Petersen, G. M., Wang, Z., Arslan, 
A. A., Beane-Freeman, L., Bracci, P. M., Buring, J., et al. (2014). Genome-wide 
association study identifies multiple susceptibility loci for pancreatic cancer. Nature 
genetics 46, 994-1000. 
Wong, N., Ojo, D., Yan, J., and Tang, D. (2015). PKM2 contributes to cancer 
metabolism. Cancer Lett 356, 184-191. 
Xue, Y., Ouyang, K., Huang, J., Zhou, Y., Ouyang, H., Li, H., Wang, G., Wu, Q., Wei, 
C., Bi, Y., et al. (2013). Direct conversion of fibroblasts to neurons by reprogramming 
PTB-regulated microRNA circuits. Cell 152, 82-96. 
Yang, L., Duff, M. O., Graveley, B. R., Carmichael, G. G., and Chen, L. L. (2011). 
Genomewide characterization of non-polyadenylated RNAs. Genome biology 12, R16. 
Yao, Z., Duan, S., Hou, D., Wang, W., Wang, G., Liu, Y., Wen, L., and Wu, M. (2010). 
B23 acts as a nucleolar stress sensor and promotes cell survival through its dynamic 
interaction with hnRNPU and hnRNPA1. Oncogene 29, 1821-1834. 
Yoshihara, K., Shahmoradgoli, M., Martinez, E., Vegesna, R., Kim, H., Torres-Garcia, 
W., Trevino, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013). Inferring tumour 
purity and stromal and immune cell admixture from expression data. Nature 
communications 4, 2612. 
You, L., Chang, D., Du, H. Z., and Zhao, Y. P. (2011). Genome-wide screen identifies 
PVT1 as a regulator of Gemcitabine sensitivity in human pancreatic cancer cells. 
Biochemical and biophysical research communications 407, 1-6. 
Zeller, K. I., Jegga, A. G., Aronow, B. J., O'Donnell, K. A., and Dang, C. V. (2003). An 
integrated database of genes responsive to the Myc oncogenic transcription factor: 
identification of direct genomic targets. Genome biology 4, R69. 
Zhang, Y., Gong, M., Yuan, H., Park, H. G., Frierson, H. F., and Li, H. (2012). Chimeric 
transcript generated by cis-splicing of adjacent genes regulates prostate cancer cell 
proliferation. Cancer discovery 2, 598-607. 
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., 
Nusbaum, C., Myers, R. M., Brown, M., Li, W., and Liu, X. S. (2008). Model-based 
analysis of ChIP-Seq (MACS). Genome biology 9, R137. 
Zhao, Q., Caballero, O. L., Levy, S., Stevenson, B. J., Iseli, C., de Souza, S. J., Galante, 
P. A., Busam, D., Leversha, M. A., Chadalavada, K., et al. (2009). Transcriptome-guided 
characterization of genomic rearrangements in a breast cancer cell line. Proceedings of 
the National Academy of Sciences of the United States of America 106, 1886-1891. 
 116 
CURRICULUM VITAE 
  
117 
  
118 
 119 
 120 
